

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 126 587
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84303128.7

(22) Date of filing: 09.05.84

(51) Int. Cl.³: **C 07 D 487/04**, C 07 D 499/00,
A 61 K 31/40, A 61 K 31/43
// C07D207/16, C07D207/24,
C07D401/12, C07D205/08,
C07F7/18,
C07F9/65, (C07D487/04, 209/00,
205/00)

(30) Priority: 09.05.83 JP 81443/83
15.06.83 JP 108472/83
12.07.83 JP 127485/83
26.09.83 JP 127485/83
09.09.83 JP 166938/83
11.11.83 JP 212857/83
10.02.84 JP 23497/84

(43) Date of publication of application: 28.11.84
Bulletin 84/48

(84) Designated Contracting States: AT BE CH DE FR GB IT
LI NL SE


(71) Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED,
15 Kitahama 5-chome Higashi-ku, Osaka-shi Osaka-fu
(JP)

(72) Inventor: Sunagawa, Makoto SUMITOMO CHEMICAL
COMPANY LIMITED, 1-98, Kasugadenaka 3-chome
Konohana-ku, Osaka-shi Osaka (JP)
Inventor: Matsumura, Haruki SUMITOMO CHEMICAL
COMPANY LTD., 1-98, Kasugadenaka 3-chome
Konohana-ku, Osaka-shi Osaka (JP)
Inventor: Inoue, Takaaki SUMITOMO CHEMICAL
COMPANY LIMITED, 1-98, Kasugadenaka 3-chome
Konohana-ku, Osaka-shi Osaka (JP)
Inventor: Fukasawa, Masatomo SUMITOMO CHEMICAL
COMPANY LTD., 2-1, Takatsukasa 4-chome,
Takarazuka-shi Hyogo (JP)
Inventor: Kato, Masuhiro SUMITOMO CHEMICAL
COMPANY LIMITED, 2-1, Takatsukasa 4-chome,
Takarazuka-shi Hyogo (JP)

(74) Representative: Diamond, Bryan Clive et al, Gee & Co.
Chancery House Chancery Lane, London WC2A 1QU
(GB)

(54) Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof.

(57) Penem compounds are of the formula:



where R₁ is H or hydroxyethyl, wherein the -OH may be protected

R₂ is H or a protective group, e.g. alkoxycarbonyl;

R₃ is H or a protective group, e.g. alkyl;

X is methylene or alkyl-methylene or S;

Y is amino (-NH₂) which may be substituted by various groups which can form a ring.

Synthesis is from a B-lactam derivative wherein the 2-position has a reactive ester alcohol group or alkylsulfinyl group, reacted with a pyrrolidinyl derivative in a solvent in presence of a base.

The compounds are useful as antimicrobial agents.

EP 0 126 587 A1

- 1 -

CARBOXYLIC THIO-PYRROLIDINYL
β-LACTAM COMPOUNDS AND PRODUCTION THEREOF


This invention relates to novel β-lactam compounds and a process for producing the same. More particularly, this invention relates to novel β-lactam compounds which are carbapenem or penem derivatives and useful as antimicrobial agents or intermediates therefor and a process for producing the same.

Since the discovery of thienamycin having a potential antimicrobial activity against Gram negative and Gram positive bacteria, studies on syntheses of carbapenem or penem derivatives which are analogous to thienamycin have been widely developed.

The present inventors have conducted intensive investigations on syntheses of carbapenem or penem derivatives and, as a result, found that carbapenem or penem derivatives having, as their 2-side chain, a substituent easily derived from 4-hydroxy-proline, i.e., a substituted pyrrolidinyl group carrying a carbonyl group substituted with various substituents on its 2-position; exhibit potential antimicrobial activity and are useful as medicines or are important intermediates for compounds possessing antimicrobial activity, and

thus completed the present invention.

The present invention relates to a novel carboxylic β -lactam compound represented by the formula (I):



wherein R_1 represents a hydrogen atom, 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group; R_2 represents a hydrogen atom or a protecting group for an amino group; R_3 represents a hydrogen atom or a protecting group for a carboxyl group; X represents a substituted or unsubstituted methylene group of the formula (1):

10



wherein R_4 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms,

or a sulfur atom; and Y represents a group of the formula (2):



wherein R_5 and R_6 , which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in its alkyl moiety, a substituted alkyl group having 1 to 5 carbon atoms or a pyridyl group, or R_5 and R_6 taken together represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a $(\text{C}_1\text{-C}_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in its ring, a substituted or unsubstituted guanidyl group of the formula (3):



wherein R_7 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, a protected or unprotected hydroxyl group, an alkoxy

group having 1 to 3 carbon atoms, an unsubstituted or (C₁-C₃) alkyl-substituted hydrazino group or a group of the formula (4):



5 wherein R₈ represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and pharmacologically acceptable salts thereof; and a process for producing the same.

10

In the above-described formula (I), the protecting group for a hydroxyl group as represented by R₁ and the protecting group for an amino group as represented by R₂ may be any of those commonly employed. Preferred examples of these protecting groups include a lower alkoxy carbonyl group, e.g., t-butyloxy carbonyl; a halogenoalkoxy carbonyl group, e.g., 2-iodoethyloxy carbonyl, 2,2,2-trichloroethyloxy carbonyl; an aralkyloxy carbonyl group, e.g., benzyloxy carbonyl, p-methoxybenzyloxy carbonyl, o-nitrobenzyloxy carbonyl, p-nitrobenzyloxy carbonyl; and a trialkylsilyl group, e.g., trimethylsilyl or t-butyldimethylsilyl.

15

20

The protecting group for a carboxyl group as represented by R_3 may be any of those commonly employed and preferred; examples are straight or branched chain lower alkyl group, e.g., methyl, ethyl, isopropyl, t-butyl; a halogeno lower alkyl group, e.g., 2-iodoethyl, 2,2,2-trichloroethyl; a lower alkoxymethyl group, e.g., methoxymethyl, ethoxymethyl, isobutoxymethyl; a lower aliphatic acyloxymethyl group, e.g., acetoxy- methyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl; a 1-lower alkoxycarbonyloxyethyl group, e.g., 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl; an aralkyl group, e.g., p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl a benzhydryl group and a phthalidyl group.

When X is a (C_1-C_3) alkyl-substituted or unsubstituted methylene group as represented by the formula (1), the (C_1-C_3) alkyl group includes, for example, methyl, ethyl, n-propyl,

When Y is an amino group represented by the formula (2), R_5 and R_6 may be the same or different from each other. In the definition of R_5 and R_6 , the alkyl group having 1 to 5 carbon atoms includes e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; the alkenyl group having 3 to 4 carbon atoms includes, for

example, propenyl, butenyl; the aralkyl group having 1 to 3 carbon atoms in its alkyl moiety includes, for example, a phenyl group, a substituted phenyl group, a pyridyl group and a (C₁-C₃) alkyl group substituted with a substituted pyridyl group, such as benzyl, substituted benzyl, phenethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl; the substituted alkyl group having 1 to 5 carbon atoms includes, for example, a straight chain or branched chain alkyl group, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, etc., which is substituted with a hydroxyl group, a di-(C₁-C₃) alkylamino group, a carbamoyl group, a mono- or di-(C₁-C₃) alkyl-substituted aminocarbonyl group, a protected or unprotected carboxyl group or a like substituent; and the pyridyl group includes 2-pyridyl, 3-pyridyl and 4-pyridyl groups.

In cases where R₅ and R₆ jointly represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C₁-C₃) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in its ring, the cyclic amino group includes, for example, a saturated cyclic amino group, e.g., an aziridino group, an azetidino group, a pyrrolidino group, a piperidino

group, etc.; an unsaturated cyclic amino group, e.g.,
a pyrrolyl group, a 3-pyrrolinyl group; and a cyclic
amino group having an oxygen atom, a sulfur atom or an
alkyl-substituted nitrogen atom in its ring, e.g., a
5 morpholino group, a thiomorpholino group, an N-methyl-
piperazino group; The substituents for these cyclic
amino groups include, for example, an alkyl group having
1 to 3 carbon atoms, a carbamoyl group, a mono- or di-
(C₁-C₃)alkyl-substituted aminocarbonyl group, a hydroxyl
10 group, etc.

When Y is represented by the formula (3), the
guanidyl group unsubstituted or substituted with a (C₁-C₃)
alkyl group includes a guanidyl group and a guanidyl group
substituted with one to four alkyl groups, e.g., methyl,
15 ethyl, n-propyl, isopropyl, , such as an N,N'-tetra-
methylguanidyl group.

The hydrazino group for Y includes, for example,
a hydrazino group and a hydrazino group substituted with
one to three alkyl groups, e.g., methyl, ethyl, n-propyl,
20 isopropyl, , such as 2',2'-dimethylhydrazino, trimethyl-
hydrazino.

In cases where Y is represented by the formula
(4), R₈ is a hydrogen atom, a protecting group commonly
employed for protection of a hydroxyl group or a lower
25 alkyl group, e.g., methyl, ethyl, n-propyl;

Of the compounds of the above-described

formula (I), the carboxylic acid compounds wherein the group as represented by $-\text{COOR}_3$ or $-\text{COY}$ is a carboxyl group can be converted into their pharmacologically acceptable salts, if desired. Such salts include those formed with inorganic metals, such as lithium, sodium, potassium, calcium, magnesium, etc. and those formed with ammonium, such as ammonium, cyclohexylammonium, diisopropylammonium, triethylammonium, etc., with a sodium salt and a potassium salt being preferred.

The preferred compounds of the formula (I) are those wherein R_1 is a hydrogen atom or a 1-hydroxyethyl group; R_2 and R_3 are both hydrogen atoms; and Y is a group represented by the formula (2-a):



wherein R_{5-a} and R_{6-a} each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in its alkyl moiety, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-(C_1 - C_3)alkylamino group, a carbamoyl group, a mono- or di-(C_1 - C_3)alkyl-substituted aminocarbonyl group, a carboxyl group, etc., or a pyridyl

group, or R_{5-a} and R_{6-a} jointly represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a (C_1-C_3) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof, wherein the substituent for the cyclic amino group includes a (C_1-C_3) alkyl group, a carbamoyl group, a carboxyl group, a mono- or di- (C_1-C_3) alkyl-substituted aminocarbonyl group, a hydroxyl group, etc.; an unsubstituted or (C_1-C_3) alkyl-substituted guanidyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; an unsubstituted or (C_1-C_3) alkyl-substituted hydrazino group; or a group represented by the formula (4-a):



wherein R_{8-a} represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms.

The more preferred compounds of the formula (I) are those wherein R_1 is a 1-hydroxyethyl group; R_2 and R_3 are both hydrogen atoms; and Y is a group represented by the formula (2-b):



wherein R_{5-b} and R_{6-b} each represents a hydrogen atom,
 an alkyl group having 1 to 5 carbon atoms, an alkenyl
 group having 3 to 4 carbon atoms, an aralkyl group having
 1 to 3 carbon atoms in its alkyl moiety, an alkyl group
 5 having 1 to 5 carbon atoms which is substituted with a
 hydroxyl group, a di-(C_1-C_3)alkylamino group, a carbamoyl
 group, a mono- or di-(C_1-C_3)alkyl-substituted aminocarbonyl
 group, a carboxyl group, etc., or a pyridyl group, or R_{5-b}
 and R_{6-b} jointly represents an alkylene chain or alkylene
 10 chain via an oxygen atom, a sulfur atom or a (C_1-C_3)alkyl-
 substituted nitrogen atom to form, together with the
 adjacent nitrogen atom, a substituted or unsubstituted 3-
 to 7- membered cyclic amino group which may contain double
 bond(s) in its ring, wherein the substituent for the cyclic
 15 amino group includes an alkyl group having 1 to 3 carbon
 atoms, a carbamoyl group, a hydroxyl group, etc.; an
 unsubstituted or (C_1-C_3)alkyl-substituted guanidyl group;
 a hydroxyl group; an alkoxy group having 1 to 3 carbon
 atoms, preferably a methoxy group; an unsubstituted or
 20 (C_1-C_3)alkyl-substituted hydrazino group; or a group
 represented by the formula (4-a):



(4-a)

wherein R_{8-a} has the same meaning as defined above.

The most preferred compounds of the formula (I) are those wherein R_1 is a 1-hydroxyethyl group; R_2 and R_3 are both hydrogen atoms; and Y is a group represented by the formula (2-c):



wherein R_{5-c} and R_{6-c} have one of the following meanings:

- (1) R_{5-c} represents an alkyl group having 1 to 5 carbon atoms which may be substituted with a carbamoyl group, a mono- or di-(C_1-C_3)alkylamino-carbonyl group, a hydroxyl group, etc., or a pyridyl group, and R_{6-c} represents a hydrogen atom or has the same meaning as described for R_{5-c} ;
- (2) R_{5-c} and R_{6-c} are directly taken together to represent an alkylene chain to form, together with the adjacent nitrogen atom, a 4- to 6-membered saturated cyclic amino group or a 5- to 6-membered unsaturated cyclic amino group having double bond(s) in its ring, such as a pyrrolinyl group, or the same saturated or unsaturated cyclic amino group as described above but having a substituent on its ring, such as a carbamoyl group, a hydroxyl

group, etc.; and

- (3) R_{5-c} and R_{6-c} jointly represent an alkylene chain via an oxygen atom or a (C_1-C_3) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 6-membered cyclic amino group.

Preferred examples of X, if positively enumerated, can include a methyl-substituted or unsubstituted methylene group represented by the formula (1-a):



wherein R_{4-a} represents a hydrogen atom or a methyl group,

with a group $\begin{array}{c} CH_3 \\ | \\ -C- \\ | \\ H \end{array}$ being particularly preferred.


The β -lactam compounds represented by the formula (I) according to the present invention are

novel compounds which are carbapenem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid) derivatives or penem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid) derivatives.

5 A process for producing the compounds of the formula (I) according to the present invention will be described below.

Of the β -lactam compounds of the formula (I), compounds represented by the formula (IV):

10




wherein R₁, R₂ and X are as defined above; R₉ represents a protecting group for a carboxyl group; and Y' represents the group as represented by the foresaid formula (2), the group as represented by the aforesaid formula (3), a protected hydroxyl group, an alkoxy group having 1 to 3 carbon atoms, an unsubstituted or (C₁-C₃)alkyl-substituted hydrazino group or a group represented by the formula (4'):

15




wherein R_8' represents a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms,

can be prepared by reacting a β -lactam derivative
5 represented by the formula (II):



wherein R_1 , X and R_9 are as defined above, and Z represents a reactive ester group of an alcohol or a substituted or unsubstituted lower alkylsulfinyl group,
10 with a mercaptan derivative represented by the formula (III):



wherein R_2 and Y' are as defined above,
in an inert solvent in the presence of a base.

15 The term "reactive ester group of an alcohol"

herein used means a group derived from a substituted or unsubstituted arylsulfonate, lower alkanesulfonate, halogeno-lower alkanesulfonate or diarylphosphoric acid ester or a halide, i.e., an ester with a hydrogen halide, of the alcohol represented by the formula (II).
5 The substituted or unsubstituted arylsulfonate includes, for example, a benzenesulfonate, a p-toluenesulfonate, a p-nitrobenzenesulfonate, a p-bromobenzenesulfonate, etc. The lower alkanesulfonate includes, for example,
10 a methanesulfonate, an ethanesulfonate). The halogeno-lower alkanesulfonate includes, for example, a trifluoromethanesulfonate. The diarylphosphoric acid ester includes, for example, a diphenylphosphoric acid ester, etc. The halide includes, for example,
15 a chloride, a bromide, an iodide, etc. Of these reactive esters of an alcohol, preferred examples are a p-toluenesulfonate, a methanesulfonate and a diphenylphosphoric acid ester.

Further, in the substituted or unsubstituted
20 lower alkylsulfinyl group, the lower alkyl group preferably includes a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. The substituent for the substituted lower alkyl group can include a hydroxyl group, a lower alkoxy group having 1 to 4
25 carbon atoms, a lower alkoxycarbonyloxy group having

2 to 5 carbon atoms, a lower alkanoyloxy group having
2 to 5 carbon atoms, an amino group, a mono- or di-
lower alkylamino group, a lower alkanoylamino group
having 2 to 5 carbon atoms, a lower alkoxycarbonylamino
5 group having 2 to 5 carbon atoms, an aralkyloxycarbonyl-
oxy group, an aralkyloxycarbonylamino group, etc.

The protecting group for a carboxyl group as
represented by R_9 corresponds to the protecting group
as represented by R_3 , and the same preferred groups as
10 enumerated for R_3 can also be applied to R_9 .

Examples of the inert solvent which can
be used in the above-described reaction are dioxane,
tetrahydrofuran, dimethylformamide, dimethyl sulfoxide,
acetonitrile, hexamethylphosphoramide and mixtures
15 thereof, with acetonitrile and dimethylformamide being
preferred.

The base also used in the reaction includes
various organic or inorganic bases, such as sodium
carbonate, potassium carbonate, sodium hydride, potassium
20 hydride, potassium t-butoxide, pyridine, various lutidines,
4-dimethylaminopyridine, triethylamine, diisopropylethyl-
amine and the like, with the organic bases, e.g., diiso-
propylethylamine, etc., being preferred.

The amount of the base to be used should be
25 enough for the reaction to sufficiently proceed and

usually ranges from 1 to 2 equivalents per mole of the mercaptan derivative of the formula (III).

The mercaptan derivative (III) is used in an amount enough for the reaction to sufficiently proceed. It may be used in a large excess but usually in an amount of from 1 to 2 equivalents based on the compound of the formula (II).

The reaction can be carried out at a temperature ranging from about -78°C to 60°C , preferably from -40°C to 40°C .

After completion of the reaction, the reaction product can be isolated by usual organochemical means.

Then, the thus obtained compound represented by the formula (IV) can be subjected, if necessary, to a reaction for removal of the hydroxyl-protecting group when R_1 is a protected hydroxyl group, a reaction for removal of the amino-protecting group, a reaction for removal of the carboxyl-protecting group R_9 , a reaction for removal of the protecting group on Y' , or an appropriate combination thereof, thereby to obtain the β -lactam compound represented by the formula (I).

The reactions for removal of the protecting groups can be carried out by generally known methods selected depending on the type of the protecting groups.


For example, those compounds of the formula (IV) wherein the hydroxyl-protecting group and/or the amino-protecting group in R_2 is/are a halogeno-alkoxycarbonyl group(s) or an aralkyloxycarbonyl group(s), and those compounds wherein the carboxyl-protecting group is a halogenoalkyl group, an aralkyl group or a benzhydryl group can be subjected to an appropriate reduction reaction to remove these protecting groups. Such reduction is preferably carried out by using an organic solvent, such as acetic acid, tetrahydrofuran, methanol, etc., and zinc in case when the protecting group to be removed is a halogenoalkoxy-carbonyl group or a halogenoalkyl group, or by catalytic reduction using a catalyst, such as platinum or palladium-on-carbon, in case when the protecting group to be removed is an aralkyloxycarbonyl group, an aralkyl group or a benzhydryl group. Solvents to be used in the catalytic reduction suitably include organic solvents, such as lower alcohols, e.g., methanol, ethanol, etc.; ethers, e.g., tetrahydrofuran, dioxane, etc.; and acetic acid, or mixed solvents of these organic solvents and water or buffer solutions, such as phosphoric acid, morpholinopropanesulfonic acid, etc. The reaction can be conducted at a temperature of from about 0°C to 100°C, preferably 0°C to 40°C, in a hydrogen atmosphere under

atmospheric pressure or under pressurized conditions.

In particular, when the protecting group to be removed is an o-nitrobenzyl group or an o-nitrobenzyloxycarbonyl group, these groups can also be removed by photo reaction.

In the compounds according to the present invention, the 5- and 6-positions of the compounds of the above-described formula (I), the 8-position of the compounds represented by the formula (V):


10



wherein R₂, R₃, X and Y are as defined above, and R₁₀ represents a hydrogen atom or a protecting group for a hydroxyl group,

the 4-position of the compounds represented by the formula (VI):

15



wherein R_1 , R_2 , R_3 , R_4 and Y are as defined above, and
 R_4 is an alkyl group,
and the 2'- and 4'-positions in the 2-side chain of the
compounds of the formulae (I), (V) and (VI) are all
5 asymmetric carbons to form isomers. Therefore, the
compounds represented by these formulae include optical
isomers and steric isomers ascribed to these asymmetric
carbon atoms. Although all of these isomers are
represented by a respective single formula for the sake
10 of convenience, the scope of the present invention is
not limited by such a single formula.

However, preferred isomers can include those
having an R-configuration at the 5-positioned carbon
atom, similarly to thienamycin, i.e., the (5R,6S)- or
15 (5R,6R)-compounds. With respect to the 8-positioned
carbon atom of the formula (V), those having an R-
configuration are preferred. Further, with respect to
the 4-position of the formula (VI), those wherein the
lower alkyl group as represented by R_4 is in a R-
20 configuration (i.e., (4R)-compounds) are preferred.


In addition, the 2'-substituted pyrrolidin-
4'-ylthio group forms four isomers, of which the
(2'S,4'S)- and (2'R,4'R)-compounds are preferred.

Particularly preferred compounds include those
25 compounds of the formula (I) having a (5R,6S,2'S,4'S)-

configuration, those compounds of the formula (V) having
a (5R,6S,8R,2'S,4'S)-configuration, and those compounds
of the formula (VI), wherein R_1 is a 1-hydroxyethyl
type substituent and R_4 is a lower alkyl group, having
5 a (4R,5R,6S,8R,2'S,4'S)-configuration.

The isomers having the above-described steric
configurations can be obtained by using the starting
compounds of the formula (II) and/or (III) having the
corresponding configurations.

10 The starting compounds (II) can be prepared
according to various known methods. For example, the
compounds represented by the formula (VII):




(VII)

wherein R_4 , R_9 and R_{10} are as defined above, and Z_0
15 represents a reactive ester group of an alcohol, and
also wherein R_4 is a hydrogen atom are known per se
in (1) Japanese Patent Application OPI (Open to
Public Inspection) No. 27169/80, (2) J. Am. Chem.
Soc., Vol. 103, 6765-6767 (1981) and (3) J. Chem. Soc.,
20 Perkin I, 964-968 (1981), etc., and the compounds (VII)
can be obtained according to the methods described in

the above-described literatures (1) to (3).

Further, the compounds (VII) can also be synthesized in accordance with the methods described in the above-described literatures (1) to (3), etc.

5 starting with compounds represented by the formula (a):




(a)

wherein R_{10} is as defined above, and Ac represents an acetyl group,

which can be obtained by the method described in

10 Tetrahedron Letters, 2293-2296 (1982) or the method described in EPC Publication No. 70204.


Furthermore, the compounds (VII) can also be obtained by subjecting a compound represented by the formula (b):



(b)

wherein DAM represents a di-p-anisylmethyl group,

which is obtained by the method disclosed in EPC
Publication No. 70204 to a carbon-increasing reaction
such as Arndt-Einstert reaction and the like and then
to an oxymercuration reaction and the like according
5 to the method of EPC Publication No. 70204, thereby
converting the ethenyl group into a 1-hydroxyethyl
group, subjecting the resulting product, if necessary,
to an appropriate combination of a reaction for
protecting or deprotecting the carboxyl group and a
10 reaction for protecting the hydroxyl group to obtain a
compound represented by the formula (c):




wherein R_{10} and DAM are as defined above,
and then obtaining the compound (VII) from the compound
15 (c) in accordance with the method described in Japanese
Patent Application OPI No. 167964/82.

The DAM group on the nitrogen atom in the
compound (c) can be removed by reacting with ceric
ammonium nitrate in an inert solvent such as aceto-
20 nitrile-water at 10 to 30°C. In this case, this reaction

may be combined with a reaction for protecting or deprotecting the carboxyl group and/or a reaction for protecting the hydroxyl group, if necessary.


Further, the compound of the formula (VII) wherein R_4 is an alkyl group can be prepared by, for example, the known method as disclosed in Japanese Patent Application OPI No. 26887/83 or analogous methods thereof.

Compounds of the formula (VIII):



wherein R_{10} is as defined above. and R_4^0 represents an alkyl group having 1 to 3 carbon atoms, which can be used as a starting material for preparing the compound (VII) wherein R_4 is an alkyl group, can be produced, for example, according to the following reaction scheme:


15



wherein R_4^0 is as defined above; R_{11} represents a protecting group for a carboxyl group; and TBDMS represents a t-butyldimethylsilyl group.

5 The compounds of the formulae (e) and (f) can be obtained as an isomeric mixture by a method described in Japanese Patent Application OPI No. 73656/80 which comprises reacting (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone

10 of the formula (d) disclosed in Chem. Pharm. Bull., Vol. 29, 2899-2909 (1981) with a halogenofatty acid ester represented by the formula:





wherein R_4^0 and R_{11} are as defined above, and X' represents a halogen atom, in a solvent, such as an ether (e.g., tetrahydrofuran, dioxane, diethyl ether, etc.), an aromatic hydrocarbon (e.g., benzene, toluene, etc.), and the like, or a mixed solvent of these solvents and hexane in the presence of diethylaluminium chloride and zinc.

Separation and purification of the isomers (e) and (f) can be carried out by silica gel column chromatography.

The compounds (e) and (f) can be led to the compound (VIII) by appropriately combining reactions for protecting or deprotecting the hydroxyl group, the carboxyl group or the nitrogen atom.

One example for the production of the starting compound (VII) will be illustrated in the following reaction scheme:





wherein R₄, R₉ and R₁₀ are as defined above; R₁₀⁰ represents a protecting group for a hydroxyl group; and
 5 Ph represents a phenyl group.

More specifically, the compound (g) obtainable by the aforesaid methods can be led to the compound (h) through the reaction described in Japanese Patent Application OPI No. 167964/82 or Heterocycles, Vol. 14,
 10 1305-1306 (1980).

The compound (h) is then reacted with a diazonizing agent, e.g., carboxybenzenesulfonazide, in the presence of a base to obtain the compound (i) as disclosed in Tetrahedron Letters, 31-34 (1980).

15 The compound (i) is then subjected to cyclization


in the presence of a metal salt catalyst, e.g., dirhodium tetrakisacetate, or by photo reaction to obtain the compound (j).

Finally, the compound (j) is reacted with diphenyl-
5 phosphoryl chloride in an inert solvent in the presence of a base such as diisopropyl ethyl amine, 4-dimethylamino-pyridine, etc. to obtain the compound of the formula (VII-a).

In general, the starting compound (VII-a) as prepared from the compound (j) is subsequently subject-
10 ed to the reaction with various mercaptans without being isolated to produce carbapenem derivatives, but the starting compound (VII-a) may be once isolated from the reaction mixture and then reacted with the mercaptan derivative (III) to obtain the desired compound of the
15 formula (IV).


Optically active reactive esters, for example, the compound (VII-a), can be obtained in the same manner as described above but starting with the β -lactam derivative (g) having the corresponding steric configu-
20 ration.

Further, of the above-described compounds of the formula (II), the compounds, for example, of the compound (IX):



wherein R_1 and R_9 are as defined above, and R_{12} represents a substituted or unsubstituted lower alkyl group,

5 can be prepared by subjecting a compound of the formula (X):




wherein R_1 , R_9 and R_{12} are as defined above, to S-oxidation using a mild oxidizing agent. The mild oxidizing agent includes perbenzoic acid, m-chloro-perbenzoic acid, hydrogen peroxide, selenium dioxide, sodium m-periodate and the like, with substituted







10 perbenzoic acids, e.g., m-chloroperbenzoic acid, etc., being preferred.



The starting compound represented by the

formula (X) can be prepared by various methods already reported, for example, the methods as disclosed in Japanese Patent Applications OPI Nos. 9034/80, 105686/80 and 81591/81.

5 On the other hand, the starting mercaptan derivative of the formula (III) can be prepared by various methods. For example, mercaptan derivatives (IIIa), (IIIb) and (IIIc) having a 2'S-configuration
 10 in accordance with the reaction scheme shown below:







In the above formulae, R_5 , R_6 and R_{11} are as defined above; R_{13} represents a protecting group for an amino group; and R_{14} represents a protecting group for a thiol group.

5 Step A:

 The reaction can easily be accomplished by various known methods generally employed for protecting an amino group of amino acids, for example, a method comprising reacting with an arylmethyloxycarbonyl chloride, etc. in the presence of a base, a method comprising using an S-acyl-4,6-dimethyl-2-mercaptopyrimidine, etc., and the like.

Step B:

 The reaction can be carried out by various methods for obtaining esters from carboxylic acids, for example, by reacting the carboxylic acid (ii) with various alkyl halides or aralkyl halides, etc. in the presence of a base.

Step C:

20 The reaction can be accomplished by various known methods for converting a hydroxyl group into a protected thiol group, for example, by a method comprising converting the carboxylic acid ester (iii) into an active ester of a hydroxyl group and then reacting with various thionizing reagents, e.g., thioacetic

25

acid, thiobenzoic acid, tritylmercaptan, etc., in the presence of a base.


This step may also be conducted by reacting the alcohol derivative with a thionizing reagent, e.g., thioacetic acid, etc., in an inert solvent, e.g., tetrahydrofuran, etc., in the presence of triphenylphosphine and diethyl azodicarboxylate.

Step D:

This step can be carried out by various known methods for converting an ester group into a carboxyl group, for example, alkali-hydrolysis, a method of using trifluoroacetic acid, hydrobromic acid, etc., or a reductive method of using zinc.

Step E:

The reaction can be achieved by various known methods for converting a carboxyl group to an amido group, for example, by a method comprising reacting with a halogenating agent, an acylating agent, etc. to form an active ester derivative and then treating the resulting ester with an amine represented by the formula:



wherein R_5 and R_6 are as defined above.

Step F:

The thiol-protecting group can be removed by various known methods for deprotection. For example, an acyl group as the thiol-protecting group
5 can be removed by alkali-hydrolysis and the like.

Step G:

The reaction can be accomplished by various known oxidation methods for converting a hydroxyl group into a carbonyl group, for example, an oxidation reac-
10 tion using chromic acid-sulfuric acid, etc. in acetone.

Step H:

The step can be conducted by various known reduction reactions for converting a carbonyl group to a hydroxyl group. For example, treatment with sodium
15 borohydride, etc. gives a mixture of the compound (iii) and the compound (ix) having different steric configurations at the hydroxyl group. The production proportion of (iii) and (ix) varies depending on reaction conditions, but each compound can be isolated as a single
20 compound by purification procedures, such as recrystallization, chromatography and the like.

Isomerization of the 4-hydroxyl group can be accomplished through the above-described steps G and H, and may also be achieved through hereinafter described
25 steps I and J.

Steps I & J:

The alcohol derivative is reacted with formic acid in an inert solvent, e.g., tetrahydrofuran, etc., in the presence of triphenylphosphine and diethyl
5 azodicarboxylate to form a formyloxy derivative (xiii), which is then subjected to alkali-hydrolysis, etc. to remove the formyl group.

Step K:

This step can be conducted by commonly employed various known methods for deprotecting amino groups,
10 for example, a method of using an acid, e.g., trifluoroacetic acid, hydrobromic acid, etc., a reducing method of using zinc, lithium-liquid ammonia, etc., or a catalytically reducing method.

15 The starting mercaptan derivatives (III) to be used for the production of the β -lactam compounds (I) wherein Y is a protected or unprotected hydroxyl group or an alkoxy group having 1 to 3 carbon atoms can be obtained by subjecting the compound (iv) or (x) to
20 Step F.

The 2'R-mercaptan (III) can be prepared by using cis-4-hydroxy-D-proline as a starting compound in accordance with the above-described method for producing 2'S-compounds, i.e., by combining various reactions
25 described in the production of the 2'S-compounds.

Of the novel β -lactam compounds represented by the formula (I) according to the present invention, those compounds in which R_1 , R_2 and R_3 are all hydrogen atoms exhibit excellent antimicrobial activity against a wide variety of disease-causing bacteria including Gram positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus faecalis, etc., and Gram negative bacteria, such as Escherichia coli, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, etc., and are useful, therefore, as antimicrobial agents. Further, these compounds have a characteristic of exhibiting excellent antimicrobial activity against β -lactamase-producing strains. Other compounds according to the present invention are important intermediates for synthesizing the above-mentioned compounds having antimicrobial activity.

In addition, the compounds according to the present invention are also characterized in general by their high physiochemical stability and excellent water solubility, although varying depending on the respective compound.

The compounds of the present invention can be used as antimicrobial agents for treating bacteria-caused infectious diseases in the form of oral preparations,

such as tablets, capsules, powders, syrups, etc. or non-oral preparations, such as intravenous injections, intramuscular injections, rectal preparations, etc.

5 The dosage of the antimicrobial agent varies depending upon the symptoms, ages, body weights, dosage forms, times of doses and the like, but usually ranges from about 100 mg to 3,000 mg per day in a single dose or several divided doses for adults. The above dose level can be increased or decreased according to
10 necessity.

Besides, the antimicrobial agent of the present invention can be administered, if necessary, in combination with dehydrodipeptidase-inhibitors, e.g., sodium Z-7-(L-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclo-
15 propanecarboxyamido)-2-heptenoate, etc. (a series of compounds disclosed in Japanese Patent Application OPI No. 81518/81).

The present invention will now be illustrated in greater detail with reference to the following
20 Reference Examples and Examples, which are given only for illustration.

"Nujol" is a paraffinic solvent.


In Reference Examples and Examples, the following abbreviations are used:

25 DAM: Di-(p-anisyl)methyl group

TBDMs: t-Butyldimethylsilyl group

PNZ: p-Nitrobenzyloxycarbonyl group
PMZ: p-Methoxybenzyloxycarbonyl group
PMB: p-Methoxybenzyl group
PNB: p-Nitrobenzyl group
5 Ph : Phenyl group
Ac : Acetyl group
Ms : Methanesulfonyl group
tBu: t-Butyl group
Me : Methyl group
10 Et : Ethyl group

Reference Example 1-1



6.55 g of trans-4-hydroxy-L-proline and 7.5 ml
of triethylamine were dissolved in 15 ml of water, and a
15 solution of 15.95 g of S-p-nitrobenzyloxycarbonyl-4,6-
dimethyl-2-mercaptopyrimidine in 35 ml of dioxane was
added thereto dropwise. The resulting mixture was stirr-
ed at room temperature for 1.5 hours and allowed to stand
overnight. To the reaction mixture was added 30 ml of a
20 2N sodium hydroxide aqueous solution under ice-cooling,
and the resulting mixture was extracted with diethyl ether.
The ethereal layer was washed with 20 ml of a 1N sodium


hydroxide aqueous solution and combined with the alkaline aqueous layer. The combined mixture was made acidic with 100 ml of a 2N hydrochloric acid aqueous solution and extracted with ethyl acetate.

5 The ethyl acetate layer was washed with a 2N aqueous solution of hydrochloric acid, dried over sodium sulfate and distilled off to remove the solvent. The resulting crude crystals were washed with warm ethyl acetate to obtain trans-1-(p-nitrobenzyloxycarbonyl)-
10 4-hydroxy-L-proline.

Melting Point: 134.3-135.5°C

IR_{max}^{Nujol} (cm⁻¹): 3300 (br.), 1738, 1660, 1605,
1520, 1340, 1205, 1172, 1070,
965

15 Reference Example 1-2



15.0 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline and 13.5 ml of triethylamine were dissolved in 150 ml of dried dimethylformamide, and
20 12.66 ml of p-methoxybenzyl chloride was added dropwise to the solution under a nitrogen stream, followed by


stirring at 70°C for 10 hours. The reaction mixture was diluted with 500 ml of ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent. Recrystallization of the residue from diethyl ether gave trans-1-(p-nitrobenzyloxy-carbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester.

Melting Point: 83-85°C

IR_{max}^{neat} (cm⁻¹): 3430, 1735, 1705, 1510, 1340,
1245, 1160

10

Reference Example 1-3



8.6 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline-p-methoxybenzyl ester and 7.86 g of triphenylphosphine were dissolved in 20 ml of dried tetrahydrofuran. To the resulting solution was added dropwise a solution of 5.22 g of diethyl azodicarboxylate in 5 ml of dried tetrahydrofuran under ice-cooling in a nitrogen stream, followed by stirring for 30 minutes at that temperature. Thereafter, 2.28 g of thioacetic acid was added thereto dropwise, and the mixture was stirred for 1 hour under ice-cooling and then at room temperature


for 3 hours, followed by concentration. The residue was purified by silica gel column chromatography to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline p-methoxybenzyl ester.

5 $\text{IR}_{\text{max}}^{\text{neat}}$ (cm^{-1}): 1740 (sh.), 1715, 1520, 1405, 1348, 1120

$\text{NMR } \delta$ (CDCl_3): 2.31 (3H, s), 3.79 (3H, s), 5.10 (2H, s), 5.24 (2H, s), 7.49 (2H, d, $J=9.0\text{Hz}$), 8.18 (2H, d, $J=9.0\text{Hz}$)ppm

10

Reference Example 1-4




9.76 g of cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline p-methoxybenzyl ester and 4.32 g of anisole were stirred together with 35 ml of trifluoroacetic acid at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline.

20

Melting Point : 107-109°C

$\text{IR}_{\text{max}}^{\text{Nujol}}$ (cm^{-1}): 1725, 1685, 1660 (sh.), 1340,

1180, 1110

Reference Example 1-5

180 mg of cis-1-(p-nitrobenzyloxycarbonyl)-
5 4-acetylthio-L-proline was dissolved in 2 ml of dried
tetrahydrofuran, and 48 mg of dimethylamine hydro-
chloride, 78 mg of N,N-dimethylaminopyridine and 152 mg
of dicyclohexylcarbodiimide were successively added
thereto, followed by stirring overnight. After any
10 insoluble matter was removed by filtration, the filtrate
was diluted with ethyl acetate, washed successively with
dilute hydrochloric acid and water, dried over sodium
sulfate and distilled off to remove the solvent. The
residue was purified by silica gel chromatography to
15 obtain (2S,4S)-cis-1-(p-nitrobenzyloxycarbonyl)-2-
dimethylcarbamoyl-4-acetylthiopyrrolidine.

The above prepared compound could also be
obtained by the following method:

200 mg of the same starting carboxylic acid
20 was dissolved in 1.8 ml of dried methylene chloride,
and one drop of dimethylformamide was added thereto.


0.12 ml of oxalyl chloride was then added dropwise thereto under ice-cooling, followed by stirring at room temperature for 1 hour. The solvent was removed by distillation, and the residue was thoroughly dried in vacuo and dissolved in 1 ml of dried tetrahydrofuran. Under ice-cooling, 1.2 ml of a 1M solution of dimethylamine in tetrahydrofuran was added to the reaction mixture, followed by stirring at that temperature for 15 minutes. To the reaction mixture was added ice-water, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent.

IR_{max}^{neat} (cm⁻¹): 1705, 1650, 1515, 1400, 1340, 1105

NMR δ (CDCl₃): 2.32 (3H, s), 2.97 (3H, s), 3.11 (3H, s), 5.21 (2H, s), 8.18 (2H, d, J=8.5Hz) ppm

$[\alpha]_D^{30} +5.21^\circ$ (c=0.379, acetone)

Reference Example 1-6




277 mg of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-hydroxycarbonyl-4-acetylthiopyridine was dissolved in 1.5 ml of dried methylene chloride, and 0.15 ml of oxalyl chloride and a catalytic amount of dimethylform-
5 amide were added thereto, followed by stirring at room temperature for 1.5 hours. The reaction mixture was distilled off to remove the solvent, and dried benzene was added to the residue. The benzene was then distilled off to remove any remaining oxalyl chloride.

10 Separately, 51 mg of pyrrole was dissolved in 2 ml of dried tetrahydrofuran, and 0.47 ml of a 1.60 mmol/ml solution of n-butyl lithium in hexane was added thereto in a nitrogen stream under ice-cooling, followed by stirring at that temperature for 40 minutes. The result-
15 ing mixture was then added in a nitrogen stream under ice-cooling to a solution of the above-described reaction residue dissolved in 2 ml of dried tetrahydrofuran, followed by stirring for 10 minutes. The resulting reaction mixture was diluted with methylene chloride,
20 washed with water, dried over sodium sulfate and distilled off to remove the solvent. The residue was purified by silica gel thin layer chromatography to obtain (2S, 4S)-1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolyl)carbonyl-4-acetylthiopyrrolidine.

25 IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm^{-1}): 1710, 1525, 1345, 1278, 1120

NMR δ (CDCl_3): 2.33 (3H, s), 5.23 (2H, s),
6.35 (2H, d, $J=2\text{Hz}$), 7.51
(2H, d, $J=9\text{Hz}$) ppm

Reference Example 1-7




368 mg of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-hydroxycarbonyl-4-acetylthiopyrrolidine was dissolved in 3 ml of dried methylene chloride, and 0.3 ml of oxalyl chloride and a catalytic amount of dimethylformamide were added thereto, followed by stirring at room temperature for 1.5 hours. The reaction mixture was distilled off to remove the solvent, and to the residue was added dried benzene. The benzene was then distilled off to remove any remaining oxalyl chloride. Separately, 128 mg of 4-carbamoylpiperidine was dissolved in 3 ml of dried tetrahydrofuran, and 0.25 ml of bistrimethylsilylaceta-
15 amide was added to the solution, followed by stirring for 3 hours in a nitrogen stream. Then, 101 mg of triethylamine was added thereto, and to the resulting mixture was added in a nitrogen stream under ice-cooling a
20 solution of the above-obtained reaction residue dissolved

in 3 ml of dried tetrahydrofuran, followed by stirring for 15 minutes under ice-cooling. Methylene chloride was added to the resulting reaction mixture. The mixture was washed successively with a sodium
 5 chloride aqueous solution, dilute hydrochloric acid, a sodium chloride aqueous solution, a sodium bicarbonate aqueous solution and a sodium chloride aqueous solution, dried over sodium sulfate and distilled off to remove the solvent. The residue was purified by silica gel
 10 thin layer chromatography to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-(4-carbamoylpiperidinyl)carbonyl-4-acetylthiopyrrolidine.

IR ν_{max} CHCl_3 (cm^{-1}): 3440, 1695, 1655, 1525, 1350,
 1120

15 NMR δ (CDCl_3) : 2.35 (3H, s), 5.21 (2H, s),
 5.93 (2H, s), 7.52 (2H, d, J=9Hz), 8.22 (2H, d, J=9Hz) ppm

Reference Example 1-8



20 40 mg of (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was dissolved

in 4 ml of methanol, and 0.1 ml of a 1N sodium hydroxide aqueous solution was added thereto, followed by stirring at room temperature for 15 minutes. 0.11 ml of a 1N hydrochloric acid aqueous solution was then added thereto, followed by concentration under reduced pressure. The concentrate was diluted with ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent to obtain (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethyl-

10

IR_{max}^{neat} (cm⁻¹): 1705, 1650, 1515, 1400, 1340,
1165, 1105


NMR δ (CDCl₃): 1.90 (1H, d, J=8Hz), 2.97 (3H, s), 3.08 (3H, s), 5.19 (2H, s),
7.48 (2H, d, J=9Hz), 8.15 (2H, d, J=9Hz) ppm

15

In the same manner as described in Reference Example 1-5 but using the corresponding amines, the following thioacetate derivatives shown in Table 1 were obtained.

20

Table 1




Reference
Example No.

Y


Spectral Data

1-9




IR_{max}^{neat} (cm⁻¹): 1700, 1660(sh), 1520, 1405, 1345, 1115

1-10



IR_{max}^{neat} (cm⁻¹): 3300, 1695, 1655, 1525, 1415, 1348, 1265, 1105

1-11



IR_{max}^{neat} (cm⁻¹): 1700, 1652, 1518, 1400, 1342, 1110


NMR₆ (CDCl₃): 1.13(3H, d, J=6Hz), 1.15(3H, d, J=6Hz), 2.34(3H, s), 5.26(2H, s), 7.53(2H, d, J=9Hz), 8.21(2H, d, J=9Hz)

0126587

Reference
Example No.

Y

Spectral Data




1-12

IR_{max} (cm⁻¹): 3320, 1680, 1520, 1430, 1405, 1345, 1120

NMR_δ (CDCl₃): 2.32(3H, s), 5.17(2H, br, s), 7.43(2H, d, J=9Hz)
8.10(2H, d, J=9Hz)


m.p. 163-167°C



1-13

IR_{max} (cm⁻¹): 3400(br), 1685, 1640(sh), 1517, 1403, 1342, 1212
1115

NMR_δ (CDCl₃): 2.33(3H, s), 2.97(3H, s), 5.20(2H, s), 7.49(2H, d, J=9Hz), 8.19(2H, d, J=9Hz)



1-14

IR_{max} (cm⁻¹): 1710, 1660, 1525, 1400, 1345, 1255, 1110


NMR_δ (CDCl₃): 2.28(3H, s), 2.30(6H, s), 2.50(3H, s), 5.17(2H, s), 7.42(2H, d, J=8.5Hz), 8.13(2H, d, J=8.5Hz)

0126587

Reference
Example No.

Y


Spectral Data



1-15

IR ν_{max} (neat cm^{-1}): 3320, 1700, 1650, 1520, 1405, 1345, 1220, 1110


NMR δ (CDCl_3): 2.33(3H, s), 2.93(3H, s), 5.23(2H, s), 7.27(5H, br, s)



1-16

IR ν_{max} (neat cm^{-1}): 1710, 1650, 1525, 1425, 1345, 1245, 1025, 962

NMR δ (CDCl_3): 1.58(6H, m), 2.32(3H, s), 5.22(2H, s)



1-17

IR ν_{max} (neat cm^{-1}): 1710, 1655, 1520, 1430, 1400, 1345, 1115

NMR δ (CDCl_3): 2.31(3H, s), 5.20(2H, s), 7.47(2H, d, $J=9\text{Hz}$), 8.18(2H, d, $J=9\text{Hz}$)

0126587

Reference
Example No.

Y

Spectral Data




Nujol (cm⁻¹): 3310, 1710, 1635, 1520, 1170, 1120
IR_{max} m.p. 200-206°C




neat (cm⁻¹): 3400, 1700, 1665, 1525, 1345, 1120
IR_{max}


NMRδ (CDCl₃): 2.33(3H, s), 7.50(2H, d, J=9Hz), 8.20(2H, d, J=9Hz)



Nujol (cm⁻¹): 3400, 3300, 3220, 1700, 1655, 1180, 1110
IR_{max} m.p. 203-209°C



Nujol (cm⁻¹): 3300, 1740, 1700, 1650, 1520, 1180
IR_{max} m.p. 185-188°C



neat (cm⁻¹): 3350, 3230, 1695, 1525, 1410, 1350
IR_{max}

NMRδ (CDCl₃): 2.37(3H, s), 3.23(3H, s), 5.20(2H, s), 7.50(2H, d, J=9Hz), 8.27(2H, d, J=9Hz)


0126587

Reference
Example No.

Y

Spectral Data


1-27



CHCl_3
 $\text{IR}_{\text{max}} (\text{cm}^{-1})$: 3350, 1690, 1660, 1520, 1340, 1120

$\text{NMR}_{\delta} (\text{CDCl}_3)$: 2.36(3H, s), 3.21(2H, s), 5.23(2H, s), 6.93(1H br.s), 7.50(2H, d, $J=9\text{Hz}$), 8.25(2H, d, $J=9\text{Hz}$)


1-28



CHCl_3
 $\text{IR}_{\text{max}} (\text{cm}^{-1})$: 1700, 1650, 1520, 1340, 1110

$\text{NMR}_{\delta} (\text{CDCl}_3)$: 2.33(3H, s), 7.43(2H, d, $J=8\text{Hz}$), 8.20(2H, d, $J=8\text{Hz}$)

1-29



$\text{IR}_{\text{max}}^{\text{neat}} (\text{cm}^{-1})$: 1695, 1655, 1525, 1427, 1342, 1250, 1110, 1065, 955


$\text{NMR}_{\delta} (\text{CDCl}_3)$: 2.32(3H, s), 5.21(2H, s), 7.48(2H, d, $J=8.5\text{Hz}$), 8.18(2H, d, $J=8.5\text{Hz}$)

0126587

Reference
Example No.

Y


Spectral Data



CHCl₃
IR_{max} (cm⁻¹): 3400, 1700, 1520, 1440, 1345, 1115

1-30


NMRδ (CDCl₃): 2.33(3H, s), 8.20(2H, d, J=9Hz)
m.p. 150-151°C



CHCl₃
IR_{max} (cm⁻¹): 3300, 1700, 1525, 1345, 1120

1-31


NMRδ (CDCl₃): 2.33(3H, s), 5.25(2H, s), 7.47(2H, d, J=9Hz),
8.58(1H, d, J=3Hz), 9.50(1H, br.s)



IR_{max} (neat) (cm⁻¹): 1705, 1655, 1520, 1430, 1400, 1342, 1112

1-32

NMRδ (CDCl₃): 2.33(3H, s), 5.20(2H, s), 7.47(2H, d, J=8.5Hz),
8.17(2H, d, J=8.5Hz)



CHCl₃
IR_{max} (cm⁻¹): 1705, 1660, 1525, 1345, 1120

1-33

NMRδ (CDCl₃): 2.35(3H, s), 5.23(2H, s), 7.55(2H, d, J=9Hz)

0126587

Reference
Example No.

Y


Spectral Data



1-34


IR_{max}^{neat} (cm⁻¹): 1705, 1640, 1516, 1430, 1400, 1342, 1110

NMR_δ (CDCl₃): 2.31(3H, s), 4.03(2H, dd, J=6 and 8Hz), 4.53(1H, t, J=8Hz), 5.19(2H, s), 7.48(2H, d, J=9Hz), 8.18(2H, d, J=9Hz)



1-35


IR_{max}^{Nujol} (cm⁻¹): 3430, 1700, 1640, 1345, 1245, 1120
m.p. 173-175°C



1-36

IR_{max}^{CHCl₃} (cm⁻¹): 3400, 1700, 1650, 1525, 1345, 1120

NMR_δ (CDCl₃): 2.33(3H, s), 5.17(2H, s), 7.47(2H, d, J=9Hz), 8.18(2H, d, J=9Hz)



1-37


IR_{max}^{neat} (cm⁻¹): 1700, 1640, 1520, 1400, 1335, 1100

NMR_δ (CDCl₃): 2.33(3H, s), 5.22(2H, s), 7.50(2H, d, J=9Hz), 8.20(2H, d, J=9Hz)

Reference
Example No.

Y


Spectral Data



1-38

IR_{max}^{neat} (cm⁻¹): 1710, 1640, 1525, 1345, 1120


NMR_δ (CDCl₃): 2.35(3H, s), 5.25(2H, s), 7.53(2H, d, J=9Hz), 8.23(2H, d, J=9Hz)



1-39

IR_{max}^{CHCl₃} (cm⁻¹): 1700, 1610, 1520, 1400, 1350, 1110

NMR_δ (CDCl₃): 2.33(3H, s), 2.87(6H, s), 2.95(6H, s), 5.25(2H, s), 7.56(2H, d, J=9Hz), 8.22(2H, d, J=9Hz)



1-40

IR_{max}^{CHCl₃} (cm⁻¹): 3350, 1705, 1610, 1525, 1345, 1120

NMR_δ (CDCl₃): 2.33(3H, s), 5.23(2H, s), 8.15(2H, d, J=8Hz)



1-41

IR_{max}^{Nujol} (cm⁻¹): 1750, 1705, 1690, 1523, 1441, 1352, 1226, 1170, 1114


m.p. 92-93.5°C

0126587

Reference
Example No.

Y

Spectral Data


1-42	-OC ₂ H ₅	IR _{max} Nujol (cm ⁻¹): 1748, 1712, 1692, 1524, 1440, 1348, 1223, 1200 m.p. 80-81.5°C
1-43	-NHNH ₂	IR _{max} Nujol (cm ⁻¹): 3200, 1720, 1615, 1520, 1350, 1125 m.p. 208-213°C
1-44	-NHN(CH ₃) ₂	IR _{max} Nujol (cm ⁻¹): 3200, 1710, 1660, 1520, 1340, 1175 m.p. 158-159°C
1-45		IR _{max} neat (cm ⁻¹): 1715, 1670, 1520, 1340, 1110 NMRδ (CDCl ₃): 2.32(3H, s), 5.18(2H, s)
1-46	-NHOPNB	IR _{max} Nujol (cm ⁻¹): 3200, 1730, 1700, 1680, 1520, 1340, 1120 m.p. 166-167°C
1-47	-NHOCH ₃	IR _{max} Nujol (cm ⁻¹): 3240, 1705, 1690, 1520, 1340, 1175 m.p. 178-179°C

Reference
Example No.

Y

Spectral Data

1-48



IR, ν_{max} neat (cm^{-1}): 1695, 1595, 1520, 1340, 1180, 1110


NMR δ (CDCl_3): 2.34(3H, s), 5.31(2H, s), 7.42(2H, d, J=6Hz), 8.48(2H, d, J=6Hz)

1-49



IR, ν_{max} neat (cm^{-1}): 1695, 1600, 1520, 1340, 1110

NMR δ (CDCl_3): 2.34(4H, s), 2.39(3H, s), 5.18(2H, s), 7.48(2H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)


Reference Example 2-1

3.10 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline and 1.10 g of triethylamine were dissolved in 40 ml of dried tetrahydrofuran, and a solution of 1.20 g of ethyl chloroformate in 10 ml of dried tetrahydrofuran was added dropwise thereto at -25°C to -35°C. After stirring at the same temperature for 50 minutes, 10 ml of concentrated aqueous ammonia was added dropwise to the mixture at -25° to -40°C. The temperature was then gradually elevated to room temperature, and the reaction mixture was stirred for 1 hour, followed by concentration under reduced pressure. To the residue were added 20 ml of water and 50 ml of diethyl ether. After ice-cooling, the thus formed white crystals were separated by filtration, washed successively with cool water and cool diethyl ether, and dried under reduced pressure to yield trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-prolineamide.

Melting Point : 163.3-164.0°C

IR_{max}^{Nujol} (cm⁻¹): 3460, 3370, 3200, 1687, 1640, 1621,

1539, 1341, 1180, 1078


Reference Example 2-2

A solution of 1.89 g of methanesulfonyl chloride in 10 ml of dried tetrahydrofuran was added dropwise to a suspension of 2.32 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-prolineamide and 1.67 g of triethylamine in 40 ml of dried tetrahydrofuran at room temperature. After stirring for 1 hour, the reaction mixture was concentrated under reduced pressure, and to the residue were added 30 ml of water and 30 ml of diethyl ether. After cooling, the resulting white crystals were separated by filtration, washed successively with cool water and cool diethyl ether and dried under reduced pressure to obtain trans-1-(p-nitrobenzyloxycarbonyl)-4-methanesulfonyloxy-L-prolineamide.

Melting Point : 149.5-151°C

IR_{max}^{Nujol} (cm⁻¹): 3400, 3225, 1715, 1675, 1520, 1340, 1170, 1135

Reference Example 2-3



A solution of 642 mg of thioacetic acid in 14 ml of dried dimethylformamide was added to a suspension of 374 mg of 50% sodium hydride in 13 ml of dried dimethylformamide in a nitrogen stream, followed by stirring at room temperature for 25 minutes. To the mixture were added 975 mg of sodium iodide and then a solution of 2.52 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-methanesulfonyloxy-L-prolineamide in 12 ml of dried dimethylformamide, and the resulting mixture was heated at 70°C for 6 hours while stirring. The reaction mixture was poured into a cool aqueous solution of sodium chloride and extracted with benzene. The extract was washed successively with a 10% aqueous solution of sodium sulfite and a sodium chloride aqueous solution, dried over sodium sulfate and distilled off to remove the solvent. The resulting crude crystals were washed with a warm mixed solvent of tetrahydrofuran and benzene to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-prolineamide.


Melting Point : 168.5-169.5°C

IR^{Nujol}_{max} (cm⁻¹): 3350, 3180, 1715, 1690, 1638,
1510, 1330, 1100

[α]_D³⁰ -23° (c=0.334, DMF)

5


Reference Example 2-4



950 mg of (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-
2-carbamoyl-4-acetylthiopyrrolidine was dissolved in
95 ml of methanol, and 2.59 ml of a 1N aqueous solution
10 of sodium hydroxide was added thereto at room temperature
in an argon stream, followed by stirring at that temper-
ature for 15 minutes. The reaction mixture was neutraliz-
ed with 2.59 ml of a 1N aqueous solution of hydrochloric
acid and distilled off under reduced pressure to remove
15 the methanol. The thus precipitated crystals were
filtered and washed with water to obtain (2S,4S)-1-(p-
nitrobenzyloxycarbonyl)-2-carbamoyl-4-mercaptopyrrolidine.

Melting Point: 158-162°C

Reference Example 3-1




A solution of 0.35 ml of dimethyl sulfoxide in 1 ml of dried methylene chloride was added dropwise to a solution of 0.2 ml of oxalyl chloride in 5 ml of dried methylene chloride at -60° to -70°C . Ten minutes later, 10 ml of a dried methylene chloride solution of 860 mg of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester was added dropwise to the above mixture at a temperature of -50°C or less, followed by stirring for 15 minutes. 1.01 g of triethylamine was then added dropwise thereto, and the resulting mixture was warmed to room temperature. The mixture was diluted with methylene chloride, washed with dilute hydrochloric acid aqueous solution and dried over sodium sulfate. The solvent was removed by distillation, and the residue was purified by silica gel column chromatography to yield 1-(p-nitrobenzyloxycarbonyl)-4-oxo-L-proline p-methoxybenzyl ester.

IR_{max}^{neat} (cm^{-1}): 1762, 1740, 1710, 1512, 1345, 1245, 1155

NMR δ (CDCl₃): 3.78 (3H, s), 3.95 (2H, s), 5.08
(2H, s), 6.85 (2H, d, J=9Hz),
8.12 (2H, d, J=9Hz) ppm

Reference Example 3-2



650 mg of 1-(p-nitrobenzyloxycarbonyl)-4-oxo-L-proline p-methoxybenzyl ester was dissolved in 45 ml. of ethanol, and 86 mg of sodium borohydride was added thereto in two divided portions at room temperature.


10 After 30 minutes, the reaction mixture was concentrated under reduced pressure at 30°C or below, and the concentrate was diluted with ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent. The residue was purified by silica gel column chromatography to obtain cis-1-(p-nitrobenzyloxycarbonyl)-
15 4-hydroxy-L-proline p-methoxybenzyl ester (450 mg) and trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester (190 mg).

Trans-compound: The IR and NMR data were consistent with those obtained for the compound of Reference Example 1-2.

Cis-compound: IR_{max}^{neat} (cm⁻¹): 3400 (br.), 1725,
1515, 1405, 1350, 1250, 1170, 1120
NMR δ (CDCl₃): 3.78 (3H, s), 5.08
(2H, s), 6.82 (2H, d, J=9Hz), 8.12
(2H, d, J=9Hz) ppm

5


Reference Example 3-3



In the same manner as described in Reference
Examples 1-3 and 1-4 but using 610 mg of cis-1-(p-
nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxy-
benzyl ester, trans-1-(p-nitrobenzyloxycarbonyl)-4-
acetylthio-L-proline was obtained.

10

Reference Example 3-4



15

a) In the same manner as described in Reference
Example 1-5 but using 180 mg of trans-1-(p-nitrobenzyl-
oxycarbonyl)-4-acetylthio-L-proline, 100 mg of (2S,4R)-1-

(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was obtained.

IR_{max}^{neat} (cm⁻¹): 1700, 1655, 1515, 1400, 1340, 1115

[α]_D³⁰ +32.8° (c=0.375, acetone)

- 5 b) In the same manner as described in Reference Example 1-8 but using 80 mg of the thioacetate derivative prepared as in a) above, (2S,4R)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.

IR_{max}^{neat} (cm⁻¹): 1700, 1650, 1510, 1420, 1400,

10

1340, 1120


NMR δ (CDCl₃): 1.77 (1H, d, J=7Hz), 2.97 (3H, s),

3.16 (3H, s), 5.22 (2H, s), 8.16

(2H, d, J=8.5Hz) ppm


- 15 In the same manner as described in Reference Example 3-4 but using the corresponding amines, the following thioacetates and mercaptans as shown in Table 2 were obtained.

Table 2



Reference Example No.	B	Y	Spectral Data
3-5	Ac	-NH ₂	IR _{neat} (cm ⁻¹): 3300(br), 1700(sh), 1685, 1512, 1430, 1400, 1345, max 1175, 1115
			[α] _D ³⁰ + 7.36° (c=0.625, acetone)
			IR _{neat} (cm ⁻¹): 1700, 1685, 1515, 1435, 1400, 1342, 1118 max
	H	-NH ₂	NMRδ (CDCl ₃): 2.26(1H, d, J=7Hz), 5.22(2H, s), 8.11(2H, d, J=8.5Hz)
3-6	Ac	-N	IR _{KBr} (cm ⁻¹): 1705, 1645, 1517, 1435, 1400, 1340, 1115 max
			NMRδ (CDCl ₃): 2.33(3H, s), 5.22(2H, s), 8.16(2H, d, J=9Hz)
	H	-N	IR _{neat} (cm ⁻¹): 1705, 1640, 1515, 1430, 1110 max

0126587

Reference Example 4-1


166 mg of cis-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline p-methoxybenzyl ester, which was
 5 obtained from cis-4-hydroxy-D-proline in the same manner as in Reference Examples 1-1 and 1-2, and 202 mg of triphenylphosphine were dissolved in 1.5 ml of dried tetrahydrofuran, and 27 mg of formic acid was added to the solution. 134 mg of diethyl azodicarboxylate
 10 further added thereto at room temperature in a nitrogen stream. After stirring for 30 minutes, the solvent was removed by distillation. The residue was purified by silica gel chromatography to obtain trans-1-p-nitrobenzyloxycarbonyl-4-formyloxy-D-proline p-methoxybenzyl
 10 ester.

IR_{max}^{neat} (cm⁻¹): 1720, 1515, 1402, 1342, 1245,
 1165, 1120

NMR δ (CDCl_3): 3.76 (3H, s), 4.50 (2H, t, J=8Hz), 5.08 (2H, s), 5.15 (2H, ABq., J=16Hz), 5.41 (1H, m), 7.97 (1H, s) ppm

5

Reference Example 4-2



215 mg of trans-1-p-nitrobenzyloxycarbonyl-4-formyloxy-D-proline p-methoxybenzyl ester was dissolved in 1.1 ml of tetrahydrofuran, and 0.93 ml of a 1N aqueous solution of sodium hydroxide was added to the resulting solution. After stirring for 10 minutes, the reaction mixture was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and distilled off to remove the solvent. The resulting residue was purified by silica gel thin layer chromatography to obtain trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline p-methoxybenzyl ester.

20


IR_{max}^{neat} (cm^{-1}): 3425 (br.), 1735, 1705, 1510, 1400, 1340, 1240, 1162

NMR δ (CDCl_3): 2.33 (2H, m), 3.58 (2H, d, J=3.5Hz),

3.73 (3H, s), 5.03 (2H, s), 5.07
 (2H, ABq., J=18Hz), 6.73 (2H, d,
 J=9Hz), 6.77 (2H, d, J=9Hz), 8.00
 (2H, d, J=8.5Hz), 8.07 (2H, d,
 J=8.5Hz) ppm

5

Reference Example 4-3



a) In the same manner as described in Reference Examples 1-3, 1-4 and 1-5 but using 110 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline p-methoxybenzyl ester, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was obtained.

10

IR_{max}^{neat} (cm⁻¹): 1705, 1650, 1515, 1435, 1340, 1115
 [α]_D³⁰ -7.38° (c=0.210, acetone)

15


b) In the same manner as described in Reference Example 1-8 but using 42 mg of the thioacetate derivative as obtained in a) above, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.

IR_{max}^{neat} (cm⁻¹): 1710, 1660, 1525, 1440, 1347, 1180,

20

1122

Reference Example 4-4




a) In the same manner as described in Reference Examples 1-3, 1-4 and 2-1 but using 110 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline p-methoxybenzyl ester, 40 mg of (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-carbamoyl-4-acetylthiopyrrolidine was obtained.

$\text{IR}_{\text{max}}^{\text{neat}}$ (cm^{-1}): 1685, 1515, 1400, 1340, 1110
 $[\alpha]_{\text{D}}^{30} +39.6^\circ$ ($c=0.293$, DMF).

b) In the same manner as described in Reference Example 1-8 but using 40 mg of the thioacetate derivative as obtained in a) above, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-carbamoyl-4-mercaptopyrrolidine was obtained.

$\text{IR}_{\text{max}}^{\text{Nujol}}$ (cm^{-1}): 3200, 1710, 1655, 1512, 1340, 1115

Reference Example 5-1



a) In the same manner as described in Reference

Examples 1-1, 1-2, 1-3, 1-4 and 1-5 but using 300 mg of cis-4-hydroxy-D-proline, 45 mg of (2R,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetyl-thiopyrrolidine was obtained.

5 IR_{max}^{neat} (cm⁻¹): 1700, 1650, 1520, 1400, 1345, 1120
 [α]_D³⁰ -29.6° (c=0.215, acetone)


b) In the same manner as described in Reference Example 1-8 but using 30 mg of the thioacetate derivative as obtained in a) above, (2R,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine
10 was obtained.

 IR_{max}^{neat} (cm⁻¹): 1710, 1655, 1520, 1430, 1405,
 1347, 1122

 In the same manner as described in Reference
15 Example 5-1 but using the corresponding amines, the following thioacetate derivatives and mercaptan derivatives as shown in Table 3 were obtained.



0126587


Table 3



Reference Example No.	B	Y	Spectral Data
5-2	Ac	-NH ₂	<p>IR, neat (cm⁻¹): 1705(sh), 1685, 1520, 1425, 1402, 1342, 1122</p> <p>[α]_D³⁰ - 6.92° (c=0.665, acetone)</p>
	H	-NH ₂	<p>IR, CHCl₃ max (cm⁻¹): 1695(sh), 1682, 1515, 1395, 1340, 1115</p>
5-3	Ac		<p>IR, neat max (cm⁻¹): 1695, 1635, 1515, 1430, 1395, 1340, 1115</p>
	H		<p>IR, CHCl₃ max (cm⁻¹): 1700, 1640, 1520, 1422, 1345, 1120</p>

0126587


Reference Example No.	B	Y	Spectral Data
Ac			<p>IR_{max} (neat, cm⁻¹): 1700, 1655, 1620, 1605, 1520, 1340, 1115</p> <p>NMR_δ (CDCl₃): 2.33(3H, s), 5.22(2H, s), 7.49(2H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)</p> <p>[α]_D²³ -21° (c=0.25, acetone)</p>
H			<p>IR_{max} (CHCl₃, cm⁻¹): 1705, 1660, 1525, 1340, 1120</p>

Reference Example 6-1

In the same manner as described in Reference Example 1-2 but using 500 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline and 383 mg of p-nitrobenzyl bromide, trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline p-nitrobenzyl ester was obtained.

IR^{CHCl₃}_{max} (cm⁻¹): 3380 (br.), 1750, 1705, 1520, 1425, 1400, 1342, 1160

NMR δ (CDCl₃) : 2.20 (3H, m), 3.67 (2H, d, J=3Hz), 4.60 (2H, t, J=8Hz), 5.15 (2H, s), 5.23 (2H, ABq.), 7.47 (4H, d, J=8.5Hz), 8.15 (4H, d, J=8.5Hz) ppm

Reference Example 6-2


In the same manner as described in Reference Examples 1-3 and 1-8 but using trans-1-p-nitrobenzyloxycarbonyl-

4-hydroxy-L-proline p-nitrobenzyl ester, cis-1-p-nitrobenzyloxycarbonyl-4-mercapto-L-proline p-nitrobenzyl ester was obtained.

IR_{max}^{neat} (cm⁻¹): 1700, 1685, 1600, 1510, 1430,
1400, 1340, 1105

5

Reference Example 6-3




a) 115 mg of cis-1-p-nitrobenzyloxycarbonyl-4-mercapto-L-proline p-nitrobenzyl ester was dissolved in 3 ml of dried tetrahydrofuran, and 30 mg of triethylamine was added thereto. Then, 28.5 mg of ethyl chloroformate was added dropwise thereto under ice-cooling, followed by stirring for 10 minutes. The reaction mixture was diluted with ethyl acetate, washed successively with dilute hydrochloric acid and water, and dried over sodium sulfate. The solvent was removed by distillation to give 133 mg of cis-1-p-nitrobenzyloxycarbonyl-4-ethoxycarbonylthio-L-proline p-nitrobenzyl ester.


IR_{max}^{neat} (cm⁻¹): 1755, 1710, 1610, 1525, 1405, 1350,
1160, 1015, 850

b) 133 mg of the thus obtained ester derivative
was dissolved in 5 ml of a mixture of tetrahydrofuran
and water (1:1 by volume), and 0.26 ml of a 1N aqueous
solution of sodium hydroxide was added thereto. After
stirring at room temperature for 2.5 hours, 0.3 ml of a
1N hydrochloric acid aqueous solution was added to the
reaction mixture, and the mixture was extracted with
ethyl acetate. The extract was washed with water, dried
over sodium sulfate and distilled off to remove the
solvent. The residue was subjected to silica gel thin
layer chromatography to obtain cis-1-p-nitrobenzyloxy-
carbonyl-4-ethoxycarbonylthio-L-proline.

IR_{max}^{neat} (cm⁻¹): 1700, 1520, 1400, 1340, 1165, 1145
NMR δ (CDCl₃): 1.30 (3H, t, J=7Hz), 4.28 (2H, q,
J=7Hz), 5.24 (2H, s), 7.50 (2H, d,
J=9Hz), 8.17 (2H, d, J=9Hz) ppm

Reference Example 6-4





a) 72 mg of cis-1-p-nitrobenzyloxycarbonyl-4-ethoxycarbonylthio-L-proline was dissolved in 3 ml of dried tetrahydrofuran, and 40 mg of triethylamine was added thereto. Under ice-cooling, 41 mg of ethyl chloroformate was added dropwise thereto, followed by stirring for 15 minutes. 1.5 ml of a 40% aqueous solution of methylamine was added dropwise to the mixture, followed by stirring for 15 minutes. The reaction mixture was diluted with ethyl acetate, washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-methylcarbamoyl-4-ethoxycarbonylthio-pyrrolidine.

IR_{max}^{Nujol} (cm⁻¹): 3290, 1705, 1660, 1520, 1425, 1405, 1345, 1180, 1160

NMR δ (CDCl₃) : 1.30 (3H, t, J=8Hz), 2.80 (3H, d, J=5Hz), 4.27 (2H, q, J=8Hz), 5.22 (2H, s), 7.48 (2H, d, J=9Hz), 8.18 (2H, d, J=9Hz) ppm

b) 82 mg of the methylcarbamoyl derivative as


prepared in a) above was dissolved in 4 ml of a mixture of methanol and water (1:1 by volume), and 0.25 ml of a 1N aqueous solution of sodium hydroxide was added thereto. After stirring at room temperature for 30 minutes, 0.27 ml of a 1N hydrochloric acid aqueous solution was added thereto. The resulting mixture was extracted with ethyl acetate, and the extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-methylcarbamoyl-4-mercaptopyrrolidine.

IR_{max}^{Nujol} (cm⁻¹): 3280, 1710, 1650, 1510, 1340, 1165

NMR δ (CDCl₃) : 2.79 (3H, d, J=5Hz), 4.27 (2H, t, J=8Hz), 5.23 (2H, s), 7.50 (2H, d, J=9Hz), 8.20 (2H, d, J=9Hz) ppm

In the same manner as described in Reference Example 6-4(a) but using the corresponding amines, the following thiocarbonates as shown in Table 4 were obtained.

Table 4




Reference
Example No.

Y

Spectral Data

6-5




IR, ν_{max} (neat, cm^{-1}): 3350, 1705, 1520, 1405, 1345, 1170, 1150

NMR δ (CDCl_3):

1.27(3H, t, $J=7\text{Hz}$), 4.23(2H, q, $J=7\text{Hz}$), 5.18(2H, s), 7.44(2H, d, $J=9\text{Hz}$), 8.13(2H, d, $J=9\text{Hz}$)

6-6



IR, ν_{max} (neat, cm^{-1}): 1710, 1520, 1400, 1345, 1170, 1148


NMR δ (CDCl_3):

1.28(3H, t, $J=7\text{Hz}$), 2.19(6H, s), 4.24(2H, q, $J=7\text{Hz}$), 5.20(2H, s), 7.47(2H, d, $J=9\text{Hz}$), 8.13(2H, d, $J=9\text{Hz}$)

0126587

The following mercaptans as shown in Table 5 were obtained in the same manner as described in Reference Example 1-8 or 6-4(b).


Table 5




Reference
Example No.

Y


Spectral Data




IR_{max}^{neat} (cm⁻¹): 1705, 1640, 1520, 1430, 1400, 1345, 1105



IR_{max}^{neat} (cm⁻¹): 3290, 1710, 1650, 1520, 1403, 1340









IR_{max}^{neat} (cm⁻¹): 3290, 1717, 1660, 1520, 1410, 1350



IR_{max}^{Nujol} (cm⁻¹): 3420, 3300, 1700(sh), 1675, 1640, 1510, 1340

0126587


Reference Example No.	Y	Spectral Data
7-5		<p>IR_{max} Nujol (cm⁻¹): 3270, 1710, 1650, 1505, 1340</p> <p>NMR δ (CDCl₃): 5.20(2H, s), 7.49(2H, q, J=8.5Hz), 8.16(2H, d, J=8.5Hz)</p>
7-6		<p>IR_{max} neat (cm⁻¹): 3400, 1690, 1640, 1515, 1405, 1345</p>
7-7		<p>IR_{max} neat (cm⁻¹): 1705, 1650, 1515, 1400, 1340</p>
7-8		<p>IR_{max} neat (cm⁻¹): 1710, 1645, 1520, 1440, 1345, 1245, 1025</p>
7-9		<p>IR_{max} neat (cm⁻¹): 1710, 1655, 1520, 1430, 1405, 1342, 1112</p>
7-10		<p>IR_{max} neat (cm⁻¹): 1710, 1650, 1520, 1405, 1345, 1205</p>

0126587

Reference
Example No.

Y'

Spectral Data



IR_{Nujol} (cm⁻¹): 3300, 1725, 1660, 1520, 1345, 1110
max




IR_{neat} (cm⁻¹): 3280, 1730(sh), 1710, 1645, 1510, 1340
max




IR_{Nujol} (cm⁻¹): 3320, 1725, 1640, 1520, 1405, 1345
max



NMR δ (CDCl₃): 1.87(1H, d, J=7Hz), 2.96(3H, s), 2.98(3H, s),
4.33(1H, t, J=7.5Hz), 5.24(2H, s), 7.48(2H, d,
J=9Hz), 8.18(2H, d, J=9Hz)



IR_{Nujol} (cm⁻¹): 3300, 1700, 1680, 1655, 1520, 1345
max




IR_{Nujol} (cm⁻¹): 3310, 1722, 1650, 1525, 1350
max

Reference
Example No.


Y

Spectral Data




IR, Nujol (cm⁻¹): 3325, 1710, 1640, 1520, 1345
max

7-17



IR, neat (cm⁻¹): 3350(br), 1690, 1660(sh), 1520, 1405, 1345
max

7-18




IR, neat (cm⁻¹): 3370, 1700, 1665, 1525, 1410, 1350
max

7-19




IR, neat (cm⁻¹): 3500, 1710, 1660, 1520, 1405, 1345
max

7-20



IR, neat (cm⁻¹): 3245, 1700, 1645, 1520, 1340, 1190, 1165, 1107,
max 1065, 950, 850

7-21



IR, neat (cm⁻¹): 3410, 1710, 1525, 1440, 1345, 1305
max

7-22

186-


0126587

Reference
Example No.

Y

Spectral Data

7-23



IR_ν Nujol (cm⁻¹): 3250, 1710, 1670, 1525, 1345, 1175
max

7-24




IR_ν neat (cm⁻¹): 1710, 1650, 1518, 1435, 1400, 1345, 1170, 1110
max

7-25




CHCl₃
IR_ν max (cm⁻¹): 1710, 1660, 1520, 1345, 1170, 1110

7-26




CHCl₃
IR_ν max (cm⁻¹): 1720, 1525, 1470, 1340, 1170, 1110

7-27



CHCl₃
IR_ν max (cm⁻¹): 3470(br), 1700, 1640, 1520, 1340, 1120

7-28



CHCl₃
IR_ν max (cm⁻¹): 3420(br), 1700, 1645, 1520, 1340, 1165

7-29




CHCl₃
IR_ν max (cm⁻¹): 1710, 1640, 1525, 1345, 1170, 1015

Reference
Example No.

Y

Spectral Data




7-30

NMR δ (CDCl₃): 1.95(1H, d, J=8Hz), 5.25(2H, s), 7.52(2H, d, J=9Hz), 8.21(2H, d, J=9Hz)



7-31

IR ν_{max} (cm⁻¹): 1705, 1600, 1520, 1400, 1340, 1160




7-32

IR ν_{max} (CHCl₃) (cm⁻¹): 3420, 1695, 1610, 1522, 1350, 1110



7-33

IR ν_{max} (neat) (cm⁻¹): 1745, 1710, 1605, 1520, 1430, 1400, 1345, 1205, 1167, 1110



7-34

IR ν_{max} (neat) (cm⁻¹): 1740, 1710, 1522, 1430, 1402, 1342, 1200, 1170, 1110



7-35

IR ν_{max} (Nujol) (cm⁻¹): 3180, 3050, 1720, 1615, 1520, 1350

0126587

Reference
Example No.

Y

Spectral Data

7-36

IR_{max}^{Nujol} (cm⁻¹): 3205, 1720, 1660, 1520, 1345, 1180

7-37

IR_{max}^{neat} (cm⁻¹): 1706, 1662, 1520, 1340, 1165, 1105


7-38

IR_{max}^{Nujol} (cm⁻¹): 3200, 1715, 1665, 1515, 1345, 1170

7-39

IR_{max}^{Nujol} (cm⁻¹): 3200, 1715, 1670, 1520, 1340, 1170


7-40

IR_{max}^{CHCl₃} (cm⁻¹): 1690, 1650, 1525, 1405, 1345, 1170, 1110

7-41

IR_{max}^{neat} (cm⁻¹): 1700, 1520, 1400, 1340, 1200, 1160, 1105


7-42

IR_{max}^{neat} (cm⁻¹): 1708, 1645, 1520, 1440, 1405, 1350, 1170, 1115

7-43

IR_{max}^{neat} (cm⁻¹): 1700, 1600, 1515, 1105

0126587

Reference Example 8-1

- a) In the same manner as described in Reference Example 1-1 but using 10 g of trans-4-hydroxy-L-proline and 23.2 g of S-p-methoxybenzyloxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine, trans-1-(p-methoxybenzyloxycarbonyl)-4-hydroxy-L-proline was obtained.

IR_{max}^{neat} (cm⁻¹): 3400 (br.), 1692, 1430, 1355, 1245, 1170, 1122

10 NMR δ (CDCl₃): 2.23 (2H, m), 3.73 (3H, s), 5.00 (2H, s), 6.78 (2H, d, J=9Hz), 7.20 (2H, d, J=9Hz) ppm

- b) In the same manner as described in Reference Example 2-1 but using 0.57 g of the proline derivative as prepared in a) above and 0.215 g of benzylamine, trans-1-p-methoxybenzyloxycarbonyl-4-hydroxy-L-benzyl-prolineamide was obtained.
- 15

0126587

IR_{max}^{Nujol} (cm⁻¹): 3375, 3300, 1665, 1248, 1165,
1120, 1025

NMR δ (CDCl₃) : 3.76 (3H, s), 4.35 (4H, m),
4.96 (2H, s), 6.79 (2H, d, J=
9Hz), 7.20 (5H, s) ppm

5

c) In the same manner as described in Reference
Example 1-3 but using 0.5 g of the benzylprolineamide
as prepared in b) above, (2S,4S)-1-p-methoxybenzyloxy-
carbonyl-2-benzylcarbamoyl-4-acetylthiopyrrolidine was
obtained.


10

IR_{max}^{Nujol} (cm⁻¹): 3280, 1690, 1675, 1240

NMR δ (CDCl₃) : 2.27 (3H, s), 3.82 (3H, s), 4.42
(2H, d, J=6Hz), 5.05 (2H, s),
6.87 (2H, d, J=8Hz), 7.23 (2H, d,
J=8Hz), 7.28 (5H, s) ppm

15

Reference Example 8-2




177 mg of (2S,4S)-1-p-methoxybenzyloxy-carbonyl-2-benzylcarbamoyl-4-acetylthiopyrrolidine and 86 mg of anisole were dissolved in 0.5 ml of trifluoroacetic acid, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed successively with an aqueous solution of sodium bicarbonate and water and dried over sodium sulfate. The solvent was removed by distillation, and the residue was subjected to silica gel thin layer chromatography to obtain (2S,4S)-2-benzylcarbamoyl-4-acetylthiopyrrolidine.

IR_{max}^{neat} (cm⁻¹): 3325, 1690, 1510, 1400, 1350, 1120, 950

NMR δ (CDCl₃): 2.28 (3H, s), 3.83 (2H, m), 4.42 (2H, d, J=6Hz), 7.32 (5H, s) ppm

Reference Example 9-1



7 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxy-2-azetidinone was dissolved in 50 ml of dried methylene chloride, and 0.8 ml of dimethylformamide

was added to the resulting solution. 2 ml of oxalyl chloride was added dropwise thereto under ice-cooling, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and to the concentrate was added 50 ml of dried methylene chloride, followed by concentration again under reduced pressure. The resulting residue was dried in vacuo and then dissolved in 100 ml of dried diethyl ether. The resulting solution was added dropwise under ice-cooling to 120 ml of a 0.17M solution of diazomethane in diethyl ether to which 4 ml of triethylamine had been added, followed by stirring at the same temperature for 1.5 hours. The reaction mixture was diluted with ethyl acetate, washed successively with a 1N aqueous solution of hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent. The resulting oily residue was purified by silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-ethenyl-4-diazoacetyl-2-azetidinone.


IR_{max}^{neat} (cm⁻¹): 2110, 1755, 1640, 1612, 1505,

1240, 1177, 1030, 828

NMR δ (CDCl₃): 3.78 (6H, s), 5.00 (1H, s), 5.80

(1H, s), 6.84 (4H, d, J=8.5Hz) ppm

Reference Example 9-2




0.7 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-diazoacetyl-2-azetidinone was dissolved in 300 ml of methylene chloride, and 1 ml of water was added thereto. The mixture was irradiated with light for 1 hour using a high pressure mercury lamp while removing oxygen from the system under ice-cooling. Then, the mixture was extracted with a 1N aqueous solution of sodium hydroxide. The aqueous layer was rendered acidic with hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent thereby obtaining 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxymethyl-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): ~3000, 1700, 1612, 1510, 1300, 1180, 1030, 820

NMR δ (CDCl₃): 2.35 (2H, d, J=6Hz), 3.73 (6H, s), 5.80 (1H, s), 6.78 (4H, d, J=9.0Hz), 7.08 (4H, d, J=9.0Hz) ppm

Reference Example 9-3




2.3 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxymethyl-2-azetidinone was dissolved in 50 ml of dried dimethylformamide, and 1.5 ml of triethylamine was added thereto. 1.3 g of p-methoxybenzyl chloride was then added dropwise to the mixture, followed by stirring at 70°C for 3 hours. The reaction mixture was diluted with ethyl acetate and diethyl ether, washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent thereby obtaining 1-(di-p-anisylmethyl)-3-ethenyl-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): 1750, 1612, 1510, 1250, 1175, 1033

NMR δ (CDCl₃): 2.36 (2H, d, J=6.5Hz), 3.72 (6H, s), 3.75 (3H, s), 4.83 (2H, s), 5.78 (1H, s) ppm


Reference Example 9-4



2.85 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone was dissolved in 14 ml of tetrahydrofuran, and 7 ml of water and 2.0 g of mercury (II) acetate were added thereto, followed by stirring at 35°C for 5 hours. 12 ml of a 1N aqueous solution of sodium hydroxide was added thereto at 0°C, and to the resulting mixture was then added dropwise a solution of 0.25 g of sodium borohydride in 1 ml of a 1N aqueous solution of sodium hydroxide. After stirring at the same temperature for 15 minutes, the reaction mixture was neutralized with a 2N hydrochloric acid aqueous solution. Diethyl ether was added thereto, followed by filtration using Celite. The filtrate was extracted with diethyl ether, and the extract was washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain 2.6 g of 1-(di-p-anisylmethyl)-3-(1-hydroxyethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): 3430, 1730, 1615, 1510, 1247, 1178, 1030, 820

NMR δ (CDCl₃): 1.23 (3H, d, J=6.5Hz), 2.42 (2H, d, J=7Hz), 3.77 (9H, s), 4.95 (2H, s), 5.78 (1H, s) ppm

Reference Example 9-5


2.6 g of 1-(di-p-anisylmethyl)-3-(1-hydroxy-ethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone
 5 was dissolved in 15 ml of dried methylene chloride, and 1.22 g of 4-dimethylaminopyridine was added thereto. Under ice-cooling, a solution of 1.3 g of p-nitrobenzyl chloroformate in 7 ml of dried methylene chloride was added dropwise to the mixture, followed by stirring at
 10 room temperature for 1 hour. To the reaction mixture were added methylene chloride and water, and the methylene chloride layer was washed successively with a 1N hydrochloric acid aqueous solution, water, a 5% aqueous solution of sodium bicarbonate and water, and dried over
 15 sodium sulfate. The solvent was removed by distillation, and the residue was purified by silica gel chromatography to obtain 2.2 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.

20 $\text{IR}_{\text{max}}^{\text{neat}} (\text{cm}^{-1})$: 1755, 1610, 1510, 1350, 1245,
 1175, 1030

NMR δ (CDCl_3): 1.35 (3H, d, $J=6.5\text{Hz}$), 2.40
(2H, d, $J=6.5\text{Hz}$), 3.09 (1H, dd,
 $J=2.5$ and 6Hz), 3.73 (6H, s),
3.77 (3H, s), 4.91 (2H, s), 5.18
(2H, s), 5.71 (1H, s) ppm

5

Reference Example 9-6



2.2 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone was dissolved in 20 ml
of dried methylene chloride, and 0.88 g of m-dimethoxybenzene and 2.5 ml of trifluoroacetic acid were added
to the solution, followed by stirring at room temperature for 4 hours. The solvent was removed by distillation,
and the resulting oily residue was subjected to silica gel chromatography to obtain 1.75 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-carboxymethyl-2-azetidinone.

10

15

$\text{IR}_{\text{max}}^{\text{neat}}$ (cm^{-1}): ~ 3000 , 1745, 1615, 1510, 1250,
1180, 1035


20

NMR δ (CDCl_3): 1.35 (3H, d, $J=6.5\text{Hz}$), 2.35 (2H,

d, J=6.5Hz), 3.10 (1H, m), 3.73 (6H, s), 5.16 (2H, s), 5.75 (1H, s), 6.73 (4H, d, J=9Hz), 7.46 (2H, d, J=9Hz), 8.10 (2H, d, J=9Hz) ppm

5

Reference Example 9-7



0.8 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-carboxymethyl-2-azetidinone was dissolved in 20 ml of dried methylene chloride, and 0.17 ml of N-methylmorpholine was added thereto. After cooling to -10°C or less, 0.15 ml of ethyl chloroformate was added dropwise thereto, followed by stirring for 30 minutes. Separately, 0.81 g of t-butyl-(p-nitrobenzyl) malonate was dissolved in 15 ml of dried tetrahydrofuran, and 0.14 g of sodium hydride (50% purity) was added to the resulting solution in a nitrogen stream under ice-cooling, followed by stirring at that temperature for 30 minutes. The resulting solution was added dropwise to the above prepared solution of a mixed anhydride at a temperature of -10°C

10

15


20

or less, followed by stirring for 1 hour. The reaction mixture was warmed to room temperature and concentrated under reduced pressure. The concentrate was diluted with cool water and ethyl acetate, washed successively with a 1N aqueous solution of hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent. The resulting residue was purified by silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-t-butoxycarbonyl-3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): 1750, 1610, 1510, 1345, 1250

NMR δ (CDCl₃): 1.38 (9H, s), 3.75 (6H, s), 5.17 (4H, s), 5.77 (1H, br. s), 6.77 (4H, d, J=8.5Hz), 7.45 (4H, d, J=9Hz), 8.15 (4H, d, J=9Hz) ppm

Reference Example 9-8



2.3 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-t-butoxycarbonyl-3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone.


(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone
 was dissolved in 120 ml of dried methylene chloride,
 and 10 ml of trifluoroacetic acid was added to the
 solution, followed by stirring at room temperature for
 5 1 hour. The reaction mixture was washed with an
 aqueous solution of sodium bicarbonate and then with
 water, dried over sodium sulfate and distilled off to
 remove the solvent. The residue was purified by silica
 gel chromatography to obtain 1-(di-p-anisylmethyl)-3-
 10 (1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitro-
 benzyloxycarbonyl)-2-oxopropyl]-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): 1748, 1720 (sh.), 1610, 1510,
 1345, 1250

NMR δ (CDCl₃): 1.41 (3H, d, J=6.5Hz), 2.61 (2H,
 15 d, J=6.5Hz), 3.27 (2H, s), 3.76
 (6H, s), 5.77 (1H, s), 6.82 (4H,
 d, J=9Hz), 7.47 (2H, d, J=9Hz),
 7.53 (2H, d, J=9Hz), 8.20 (4H, d,
 J=9Hz) ppm

20


Reference Example 9-9



1.9 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone and 660 mg of p-carboxybenzenesulfonyl azide were dissolved in 50 ml of dried acetonitrile, and 1.4 ml of triethylamine was added thereto dropwise in a nitrogen stream under ice-cooling. After stirring at that temperature for 15 minutes, the reaction mixture was diluted with ethyl acetate, and the thus formed precipitate was filtered. The filtrate was concentrated under reduced pressure, and the resulting oily residue was subjected to silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazopropyl]-2-azetidinone.

IR_{max}^{neat} (cm⁻¹): 2150, 1750, 1720 (sh.), 1650, 1510, 1250, 1350

NMR δ (CDCl₃): 1.38 (3H, d, J=6.5Hz), 2.95 (2H, d, J=6.5Hz), 3.73 (6H, s), 5.17 (2H, s), 5.24 (2H, s), 5.74 (1H, s), 6.71 (2H, d, J=9Hz), 6.76 (2H, d, J=9Hz), 7.08 (2H, d, J=9Hz), 7.14 (2H, d, J=9Hz), 7.42 (4H, d, J=9Hz), 8.11 (2H, d, J=9Hz), 8.16 (2H, d, J=9Hz) ppm

Reference Example 9-10

1.27 g 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazopropyl]-2-azetidinone was dissolved in 50 ml of acetonitrile-water (9 : 1 by volume), and 2.7 g of ceric ammonium nitrate was added thereto all at once under ice-cooling. After vigorously stirring, the mixture was further stirred at room temperature for 30 minutes. Cool water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and dried over sodium sulfate. The solvent was distilled off, and the resulting residue was purified by silica gel chromatography to obtain 3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazopropyl]-2-azetidinone.


IR_{max}^{neat} (cm⁻¹): 2145, 1750, 1720, 1650, 1520, 1345, 1260

NMR δ (CDCl₃): 1.45 (3H, d, J=6.5Hz), 3.01 (1H,

dd, J=9 and 18Hz), 3.29 (1H, dd, J=4.5 and 18Hz), 4.00 (1H, m), 5.24 (2H, s), 5.36 (2H, s), 6.12 (1H, s), 7.55 (4H, d, J=8.5Hz), 8.21 (2H, d, J=8.5Hz), 8.25 (2H, d, J=8.5Hz) ppm

5

Reference Example 9-11



10 a) 0.55 g of 3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazo-propyl]-2-azetidinone was dissolved in 25 ml of degassed dried benzene, and a catalytic amount of rhodium (II) acetate was added thereto. After blowing nitrogen gas into the mixture for about 3 minutes, the mixture was
15 refluxed for 20 minutes, followed by cooling. The catalyst was separated by filtration and washed with benzene. The filtrate and the washing were combined

and concentrated under reduced pressure to yield
p-nitrobenzyl-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylate.

IR_{max}^{neat} (cm⁻¹): 1770, 1745, 1520, 1350, 1260

5 NMR δ (CDCl₃): 1.50 (3H, d, J=6.5Hz), 2.50 (1H,
dd, J=8.0 and 18Hz), 2.89 (1H,
dd, J=7.0 and 18Hz), 3.39 (1H,
dd, J=2.0 and 8.0Hz), 4.14 (1H,
dt, J=2.0 and 7.0Hz), 4.77 (1H,
10 s), 5.26 (4H, s), 7.52 (4H, d,
J=8.5Hz), 8.21 (4H, d, J=8.5Hz) ppm

b) The keto ester derivative as obtained in a)
above was dissolved in 25 ml of dried acetonitrile, and
195 mg of diisopropylethylamine was added thereto under
15 ice-cooling. To the resulting mixture was added drop-
wise a solution of 300 mg of diphenyl chlorophosphate
in 2 ml of dried acetonitrile, followed by stirring for
1 hour. The reaction mixture was diluted with ethyl
acetate, washed with water, and dried over magnesium
20 sulfate. The solvent was removed by distillation under
reduced pressure to obtain p-nitrobenzyl-5,6-trans-3-
(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxy-
ethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate.

IR_{max}^{neat} (cm⁻¹): 1780, 1745, 1585, 1517, 1480, 1345,
25 1295, 1255, 1180, 1158, 965


NMR δ (CDCl_3): 1.46 (3H, d, $J=6.5\text{Hz}$), 3.24 (2H, br. d, $J=8.5\text{Hz}$), 3.40 (1H, dd, $J=3.0$ and 8.5Hz), 5.24 (2H, s), 5.32 (2H, ABq, $J=13\text{Hz}$), 7.28 (10H, s), 7.53 (4H, d, $J=8.5\text{Hz}$), 8.14 (2H, d, $J=8.5\text{Hz}$), 8.23 (2H, d, $J=8.5\text{Hz}$) ppm

5

10

Further, by using (3R,4S)-1-(di-p-anisyl-methyl)-3-ethenyl-4-carboxy-2-azetidinone [optical rotation $[\alpha]_D^{22} = +63.3^\circ$ ($c=0.12$, CHCl_3)], (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate was obtained.

Reference Example 10-1



To 1.33 g (20 mM) of activated zinc was added 20 ml of dried tetrahydrofuran, and 8.8 ml of a 15% n-hexane solution of diethylaluminium chloride was added thereto in a nitrogen stream under ice-cooling. A solution prepared by dissolving 1.49 g (5.2 mM) of (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone (1) and 3.73 g (15.3 mM) of benzyl α -bromopropionate in 13.3 ml of dried tetrahydrofuran was added dropwise to the mixture over a period of 30 to 40 minutes, followed by stirring for 1 hours. Under ice-cooling, 2.8 ml of pyridine, 13.2 ml of water, 26.5 ml of ethyl acetate and 13.2 ml of a 1N hydrochloric acid aqueous solution were successively added thereto, and the resulting mixture was filtered using Celite. The filtrate was washed with water, and the organic layer was dried over sodium sulfate and distilled off to remove the solvent. The resulting oily residue was subjected to silica gel column chromatography to obtain an isomeric mixture of 4-(1-benzyloxycarbonyl)-ethyl-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone.

The isomeric mixture was separated into each compound by Lober column chromatography using silica gel and 1.5% isopropanol/n-hexane as an eluent to obtain the compound (2a) and the compound (2b) as oily substances.


Isomer (2b)

IR_{max}^{neat} (cm⁻¹): 1755, 1460, 1377, 1252, 1100,
835

NMR δ (CDCl₃): 0.06 (6H, s), 0.87 (9H, s),
1.16 (3H, d, J=6.5Hz), 1.19
(3H, d, J=7.0Hz), 3.71 (1H,
dd, J=2 and 10Hz), 5.14 (2H, s),
7.35 (5H, s) ppm

Isomer (2a)

NMR δ (CDCl₃): 0.06 (6H, s), 0.87 (9H, s), 1.08
(3H, d, J=6.5Hz), 1.18 (3H, d,
J=7.0Hz), 3.91 (1H, dd, J=2.2
and 5.5Hz), 4.17 (2H, q, J=6Hz),
5.12 (2H, s), 7.35 (5H, s) ppm

Reference Example 10-2


200 mg of 4-(1-benzyloxycarbonyl)ethyl-3-
[(R)-1-(t-butyl-dimethylsilyloxy)ethyl]-2-
azetidinone (2a) was dissolved in 2 ml of dried dimethyl-
formamide. 126 mg of triethylamine was added to the

resulting solution, and then 151 mg of *t*-butyldimethylsilyl chloride was added thereto, followed by stirring at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water, dried over sodium sulfate and purified by silica gel chromatography to obtain 4-(1-benzyloxycarbonyl)ethyl-3-[(R)-1-(*t*-butyldimethylsilyloxy)ethyl]-1-(*t*-butyldimethylsilyl)-2-azetidinone (3a).

IR_{max}^{neat} (cm⁻¹): 1750, 1465, 1325, 1255, 835

10

Reference Example 10-3



15


184 mg of 4-(1-benzyloxycarbonyl)ethyl-3-[(R)-1-(*t*-butyldimethylsilyloxy)ethyl]-1-(*t*-butyldimethylsilyl)-2-azetidinone (3a) was dissolved in 4 ml of methanol, and the resulting solution was stirred together with 20 mg of 10% palladium-on-carbon at an atmospheric pressure of hydrogen for 2 hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 4-(1-carboxy)ethyl-3-[(R)-1-(*t*-butyldimethylsilyloxy)-

20

ethyl-1-(*t*-butyldimethylsilyl)-2-azetidinone (4a).

IR_{max}^{neat} (cm⁻¹): 1740, 1465, 1330, 1255, 1043, 837


Reference Example 10-4



5 (4R,5R,6S,8R)-*p*-Nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-3,7-dione-2-carboxylate was obtained from 170 mg of 4-(1-carboxy)-ethyl-3-[(*R*)-1-(*t*-butyldimethylsilyloxy)ethyl]-1-(*t*-butyldimethylsilyl)-2-azetidinone (4a) according to the
10 method described in Japanese Patent Application OPI No. 26887/83, pages 64-65.

IR_{max}^{neat} (cm⁻¹): 3450 (br.), 1770 (sh.), 1750, 1605, 1520, 1350, 1217, 1180

Reference Example 11




To a solution of 261 mg of (5R,6S,8R)-*p*-

nitrobenzyl-3-ethylthio-6-(1-hydroxyethyl)-1-aza-
bicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate in
28 ml of dried methylene chloride, 144 mg of m-chloro-
perbenzoic acid was added at -45°C in a nitrogen stream,
5 followed by stirring at -20° to -40°C for 2 hours. The
reaction mixture was washed with a saturated aqueous
solution of sodium bicarbonate and then with water,
dried over sodium sulfate and distilled off to remove
the solvent. The resulting residue was purified by
10 silica gel chromatography to obtain (5R,6S,8R)-p-nitro-
benzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo-
[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate.

IR_{max} CHCl_3 (cm^{-1}): 1793, 1703, 1605, 1517, 1447,
1377, 1344, 1315, 1172, 1112,
15 1043, 965, 824

NMR δ (CDCl_3): 5.74 (3/5H, d, $J=1.5\text{Hz}$), 5.87
(2/5H, d, $J=1.5\text{Hz}$) ppm

Example 1-1



- a) 122 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was dissolved in 3 ml of dry acetonitrile, and 31 mg of diisopropylethylamine was added thereto in a nitrogen stream under ice-cooling. Then, 60 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

$IR_{\text{max}}^{\text{neat}}$ (cm^{-1}): 1780, 1745, 1705, 1650, 1605, 1515,
1342, 1257

NMR $\delta(\text{CDCl}_3)$: 1.49 (3H, d, $J=6\text{Hz}$), 2.99 (3H, s),
3.11 (3H, s), 5.25 (4H, s), 5.23 and
5.46 (2H, ABq, $J=14\text{Hz}$), 7.53 (4H, d,
 $J=8.5\text{Hz}$), 7.62 (2H, d, $J=8.5\text{Hz}$),
8.18 (6H, d, $J=8.5\text{Hz}$)

$[\alpha]_{\text{D}}^{28} +7.7^\circ$ ($c=0.303$, acetone)


b) 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-
[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-
pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was
dissolved in 20 ml of dioxane, and a morpholinopropane-
sulfonic acid buffer solution ($\text{pH} = 7.0$, 10 ml) and
platinum oxide (35 mg) were added thereto. The mixture
was then hydrogenated under a hydrogen pressure of 3.5 atm.
for 6.5 hours. The catalyst was filtered off and dioxane
was distilled off under reduced pressure. The residual
solution was washed with ethyl acetate, and the aqueous
layer was again distilled under reduced pressure to remove
the organic solvent. The residual solution was subjected
to polymer chromatography (CHP-20P) to obtain (5R,6S,
8R,2'S,4'S)-3-[4-(2-dimethylaminecarbonyl)pyrrolidinyl-
thio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-
7-one-2-carboxylic acid from the fraction eluted with
water.

UV^{H₂O}_{max} nm: 297

IR^{KBr}_{max} cm⁻¹: 1755, 1627, 1393, 1252, 1130

NMR δ (D₂O): 1.25 (3H, d, J=6.4Hz), 1.81-1.96 (1H, m),
2.96 (3H, s), 3.03 (3H, s), 3.14-3.20
(3H, m), 3.31-3.41 (2H, m), 3.62-3.72
(1H, m), 3.90-4.00 (1H, m), 4.14-4.26
(2H, m), 4.63 (1H, t, J=8.5Hz)

Example 1-2



10 a) In the same manner as described in Example 1-1(a)
but using 129 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenyl-
phosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and
67 mg of [2S,4R]-1-p-nitrobenzyloxycarbonyl-2-dimethyl-
15 aminocarbonyl-4-mercaptopyrrolidine, there was obtained
40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-[4-(1-p-
nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)pyrrolidinyl-
thio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo-
[3,2,0]hept-2-ene-7-one-carboxylate.

20 IR^{neat}_{max} (cm⁻¹): 1775, 1745, 1705, 1650, 1520, 1400,
1345, 1260, 1130

NMR δ (CDCl₃): 1.48 (3H, d, J=6Hz), 2.96 (3H, s),
 3.12 (3H, s), 5.22 (4H, s), 7.44, 7.50
 and 7.58 (each 2H, d, J=8.5Hz), 8.17
 (6H, d, J=8.5Hz)


5 $[\alpha]_D^{27} +31.1^\circ$ (c=0.193, acetone)

b) In the same manner as described in Example 1-1(b)
 but using 40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-
 [4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-
 pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
 10 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there
 was obtained (5R,6S,8R,2'S,4'R)-3-[4-(2-dimethylamine-
 carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-
 [3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV^{H₂O}_{max} nm: 297

15

Example 1-3



a) In the same manner as described in Example 1-1(a)
 but using 61 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenyl-
 phosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-
 20 azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and 31 mg
 of [2R,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylamine-

carbonyl-4-mercaptopyrrolidine, there was obtained 37 mg
of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-[4-(1-p-nitro-
benzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-
6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo-
5 [3,2,0]hept-2-ene-7-one-2-carboxylate.


IR_{max}^{neat} (cm⁻¹): 1775, 1745, 1705, 1650, 1520, 1400,
1345, 1260, 1130

NMR δ (CDCl₃): 1.49 (3H, d, J=6.5Hz), 2.98 (3H, s),
3.16 (3H, s), 5.27 (4H, s), 5.19 and
10 5.47 (2H, ABq, J=14Hz), 7.50, 7.55 and
7.64 (each 2H, d, J=8.5Hz), 8.20 (4H,
d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz)

$[\alpha]_D^{29} +26.8^\circ$ (c=0.243, acetone)

b) In the same manner as described in Example 1-1(b)
15 but using 37 mg of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-
[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-
pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there
was obtained (5R,6S,8R,2'R,4'S)-3-[4-(2-dimethylamine-
20 carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-
[3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV_{max}^{H₂O} nm: 297

Example 1-4

a) In the same manner as described in Example 1-1(a) but using 76 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate and 39 mg of [2R,4R]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl-4-mercaptopyrrolidine, there was obtained 35 mg of (5R,6S,8R,2'R,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate.

IR_{max}^{neat} (cm⁻¹): 1775, 1745, 1705, 1650, 1520, 1440, 1342, 1260, 1120

15 NMR δ (CDCl₃): 1.49 (3H, d, J=6.5Hz), 2.98 (3H, s), 3.09 (3H, s), 5.25 (4H, s), 5.26 and 5.44 (2H, ABq, J=14Hz), 8.20 (6H, d, J=8.5Hz)

$[\alpha]_D^{30}$ +23.3° (c=0.329, acetone)


b) In the same manner as described in Example 1-1(b) but using 35 mg of (5R,6S,8R,2'R,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2'R,4'R)-3-[4-(2-dimethylamino-

5 carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV^{H₂O}_{max} nm: 297

10

Example 2



a) 53 mg of (4R,5R,6S,8R)-p-nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-3,7-dione-2-carboxylate was dissolved in 5 ml of dry acetonitrile, and 57 mg of diisopropylethylamine and then 43 mg of diphenyl chlorophosphate were added thereto. After stirring for 2.5 hours, 57 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 35 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

IR_{max}^{neat} (cm⁻¹): 1760, 1705, 1645, 1520, 1402, 1342, 1135, 1110

NMR δ (CDCl₃): 1.30 (3H, d, J=7.0Hz), 1.35 (3H, d, J=6.5Hz), 2.99 (3H, s), 3.02 (3H, d, J=15Hz), 5.21 (2H, s), 5.20 and 5.43 (2H, ABq, J=14Hz), 7.51 (2H, d, J=8.5Hz), 7.64 (2H, d, J=8.5Hz), 8.20 (4H, d, J=8.5Hz)


b) 25 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-pyrrolidinylthiol]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate was dissolved in
5 a mixture of 1.9 ml of tetrahydrofuran and 0.3 ml of ethanol, and the mixture was hydrogenated in a morpholino-propanesulfonic acid buffer solution (pH = 7.0, 1.9 ml) under atmospheric pressure of hydrogen for 3 hours at room temperature in the presence of 30 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere
10 for 1 hour followed by washing with water.
After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate.
15 The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5R,6S,8R,2'S,4'S)-3-[4-(2-dimethylamine-carbonyl)pyrrolidinylthiol]-4-methyl-6-(1-hydroxyethyl)-
20 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with water.

UV^{H₂O}_{max} nm: 296

NMR δ (D_2O): 1.21 (3H, d, $J=7.0\text{Hz}$), 1.29 (3H, d, $J=6.5\text{Hz}$), 1.92 (1H, m), 2.99 (3H, s), 3.06 (3H, s)

Example 3

5



a) 61 mg of (4R,5R,6S,8R)-p-nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-3,7-dione-2-carboxylate was dissolved in 6 ml of dry acetonitrile, and 72 mg of diisopropylethylamine and then 55 mg of diphenyl chlorophosphate were added thereto in a nitrogen stream under ice-cooling, followed by stirring for 2.5 hours. 77 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinecarbonyl)-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 51 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinecarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-

10

15

20

one-2-carboxylate.

IR_{max}^{neat} (cm⁻¹): 1760, 1710, 1640, 1525, 1440, 1350,
1210, 1110

5 NMR δ(CDC1₃) : 1.30 (3H, d, J=7.0Hz), 1.34 (3H, d,
J=6.5Hz), 5.21 (2H, s), 5.20 and 5.44
(2H, ABq, J=14Hz), 7.50 (2H, d, J=8.5Hz),
7.64 (2H, d, J=8.5Hz), 8.20 (4H, d,
J=8.5Hz)


b) 50 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-
10 3-[1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinecarbonyl)-
pyrrolidin-4-ylthiol-4-methyl-6-(1-hydroxyethyl)-1-
azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was
dissolved in a mixture of 3.9 ml of tetrahydrofuran and
0.6 ml of ethanol, and the mixture was hydrogenated in a
15 morpholinopropanesulfonic acid buffer solution (pH = 7.0,
3.9 ml) under atmospheric pressure of hydrogen for 4.5 hours
at room temperature in the presence of 60 mg of 10% pal-
ladium-carbon, which had been activated in hydrogen
atmosphere for 1 hour followed by washing with water.
20 After filtering off the catalyst, tetrahydrofuran
and ethanol were distilled off under reduced pressure,
and the residual solution was washed with ethyl
acetate. The aqueous layer was again distilled under
reduced pressure to remove organic solvents, and the

residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5R,6S,8R,2'S,4'S)-3-[2-(1-pyrrolidinecarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.

UV_{max}^{H₂O} nm : 297

NMR δ (D₂O); 1.20 (3H, d, J=7.0Hz), 1.28 (3H, d, J=6.5Hz), 1.95 (6H, m), 3.46 (6H, m), 3.72 (1H, dd, J=6.5 and 12Hz), 4.02 (1H, quintet, J=6.5Hz)

Example 4



a) 172 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was dissolved in 2.3 ml of dry acetonitrile, and to the solution were added a solution of 59 mg of diisopropylethylamine in 0.7 ml of dry acetonitrile and then a solution of 94 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)-4-mercaptopyrrolidine in 1 ml of dry aceto-

nitride, in a nitrogen stream and under ice-cooling,
 followed by stirring for 15 minutes. The reaction
 solution was diluted with diethyl ether, washed with
 water, and the insoluble material in the ether layer
 5 was dissolved with addition of methylene chloride.
 The methylene chloride and ether layer was dried over
 magnesium sulfate and the solvent was distilled off.
 The residue was purified by silica gel thin layer chromato-
 graphy to obtain 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-
 10 3-{4-[1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)]-
 pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-
 1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

IR^{CHCl₃}_{max} (cm⁻¹): 1780, 1745, 1708, 1660, 1623, 1606,
 1520, 1342

15 NMR δ (CDCl₃): 1.49 (3H, d, J=6.2Hz), 5.26 (4H, s),
 8.18 (6H, d, J=8.8Hz)

b) 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-
 3-{4-[1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-
 carbonyl)]pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyl-
 20 oxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-
 carboxylate was dissolved in a mixture of 12.6 ml of
 tetrahydrofuran and 2 ml of ethanol, and the solution was
 hydrogenated in a morpholinopropane-
 sulfonic acid buffer solution (pH = 7.0, 12.6 ml)
 25 at room temperature under atmospheric pressure of hydrogen


for 7 hours in the presence of 219 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere for 1 hour, followed by washing with water. After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate. The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-{4-[2-(3-pyrroline-1-carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.

15 UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 298

IR $_{\text{max}}^{\text{KBr}}$ (cm^{-1}): 1755, 1640, 1595, 1450, 1380, 1245

NMR δ (D_2O): 1.26 (3H, d, $J=6.4\text{Hz}$), 3.18 (1H, dd, $J=2.1$ and 9.0Hz), 3.77 (1H, dd, $J=7.0$ and 12.0Hz), 5.89 (2H, br. s)

Example 5



a) Following the procedures as described in Example 1-1(a) using 68 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and 33 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminecarbonyl-4-mercaptopyrrolidine, there was obtained 61 mg of crystalline (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate by filtration.

IR_{max}^{Nujol} (cm⁻¹): 3445, 3300, 1790, 1745, 1710, 1670, 1635, 1510, 1345, 1270

NMR δ (CDCl₃): 1.50 (3H, d, J=6.5Hz), 5.23 (4H, s), 7.50 (4H, d, J=8.5Hz), 8.21 (6H, d, J=8.5Hz)

m.p.: 184-189°C (dec.)


b) 30 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylamine-carbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate
5 was dissolved in a mixture of 3.1 ml of tetrahydrofuran and 1 ml of dimethylformamide, and the solution was hydrogenated in the presence of a morpholinopropane-sulfonic acid buffer solution (pH = 7.0, 3.1 ml) at room temperature under atmospheric pressure of hydrogen
10 for 5 hours in the presence of 37 mg of 10% palladium-carbon which had been activated in hydrogen atmosphere for 1 hour followed by washing with water. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure, and the residual solution was
15 washed with methylene chloride. The aqueous layer was distilled to remove the organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-[4-(2-carbamoylmethylaminecarbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-
20 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with water.

UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 300

IR KBr_{max} (cm^{-1}): 1745, 1665, 1590, 1390, 1220, 1180, 1040

NMR δ (D₂O): 1.26 (3H, d, J=6.6Hz), 1.86 (1H, m),
 3.20 (2H, dd, J=7.5 and 14.7Hz), 3.38
 (1H, dd, J=3.0 and 6.7Hz), 4.02 (1H, t,
 J=9.0Hz)

5

Example 6

a) To a solution of 45 mg of (5R,6S,8R)-p-nitrobenzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylate in 0.8 ml
 10 of dry acetonitrile were added a solution of 30 mg of diisopropylethylamine in 0.3 ml of dry acetonitrile and then a solution of 81 mg of (2'S,4'S)-1'-p-nitrobenzyl-oxycarbonyl-2-dimethylaminocarbonyl-4'-mercaptopyrrolidine in 0.6 ml of dry acetonitrile under nitrogen stream at
 15 -40°C, followed by stirring the mixture at -40°C to -45°C for 10 minutes. The reaction solution was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, and the solvent was distilled off. The resulting residue was
 20 purified by silica gel chromatography to obtain (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-

2-dimethylaminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxy-ethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylate.

$$[\alpha]_D^{29} +52^\circ \text{ (c=0.43, CHCl}_3\text{)}$$

5 IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm^{-1}): 1788, 1700, 1660, 1607, 1400, 1325, 1114, 1013

NMR δ (CDCl_3): 1.32 (3H, d, $J=6\text{Hz}$), 2.96 (3H, s),
3.08 (3H, s), 3.72 (1H, dd, $J=1.5\text{Hz}$
and $J=6\text{Hz}$), 5.20 (2H, s), 5.70 (1H, d,
10 $J=1.5\text{Hz}$)

b) 204 mg of 5% palladium-carbon was suspended in a mixture of ethanol (3.8 ml) and water (3.8 ml) and hydrogenated at room temperature under atmospheric pressure for 1 hour. The catalyst was filtered, washed
15 with water, suspended in a phosphate buffer (pH = 6.86, 5.1 ml); and added to a solution of 68 mg of (5R,6S,8R, 2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxy-ethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-
20 carboxylate in 7.7 ml of tetrahydrofuran. The mixture was hydrogenated at room temperature and under atmospheric pressure for 3 hours. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure.

The residual solution was washed with ethyl acetate, and the aqueous layer was again distilled under reduced pressure to remove the organic solvents. The resulting residual solution was purified by CHP-20P column

5 chromatography to obtain (5R,6S,8R,2'S,4'S)-2-[(2-dimethyl-aminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylic acid.

UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 322, 255

10 IR $\nu_{\text{max}}^{\text{KBr}}$ (cm^{-1}): 1765, 1645, 1580, 1508, 1367


NMR δ (D_2O): 1.29 (3H, d, $J=6.4\text{Hz}$), 1.94 - 2.08
(1H, m), 2.93 - 3.15 (1H, m), 2.98
(3H, s), 3.05 (3H, s), 3.53-3.62 (1H, m),
3.83 - 3.93 (1H, m), 3.94 (1H, dd,
15 $J=1.4\text{Hz}$ and $J=6\text{Hz}$), 4.06 - 4.30 (3H, m),
5.71 (1H, d, $J=1.4\text{Hz}$)

Examples 7 to 90

The compounds shown in Table 6 below were prepared from the corresponding mercaptan derivatives.

20 In Table 6, "HE" represents (R)-1-hydroxyethyl group, and "PNZE" represents (R)-1-p-nitrobenzyloxycarbonyloxyethyl group.

Table 6


Example
No. R_1 R_2 R_3

Y

Spectral Data

 $\text{IR}_{\text{Nujol}} (\text{cm}^{-1}): 3420, 1785, 1742, 1710, 1677, 1510,$
 $\text{max} \quad 1342, 1255$

PNZE PNZ PNB







m.p. 138-142°C

 $[\alpha]_D^{30} +44.4^\circ$ (c=0.105, DMF)

 H_2O
 $\text{UV}_{\text{max}} \text{ nm: } 297$
 $\text{IR}_{\text{KBr}} (\text{cm}^{-1}): 1752, 1687, 1595, 1385$
 $\text{NMR } \delta (\text{D}_2\text{O}):$
 $1.24(3\text{H}, \text{d}, J=6.5\text{Hz}), 2.0-2.15(1\text{H},$
 $\text{m}), 2.83-2.98(1\text{H}, \text{m}), 3.17(2\text{H}, \text{d},$
 $J=9\text{Hz}), 3.32-3.42(2\text{H}, \text{m}), 3.71-$
 $3.80(1\text{H}, \text{m}), 3.98(1\text{H}, \text{quintet};$
 $J=7\text{Hz}), 4.13-4.32(1\text{H}, \text{m}), 4.41(1\text{H}, \text{t},$
 $J=8.5\text{Hz})$


HE H H

 $[\alpha]_D^{30} -25^\circ$ (c=0.05, H_2O)

sample no.	R ₁	R ₂	R ₃	Y	Spectral Data
8	PNZE	PNZ	PNB		IR _ν neat (cm ⁻¹): 1775, 1745, 1700, 1665(sh), 1515, 1345, 1257 NMR δ (CDCℓ ₃): 1.48(3H, d, J=6.5Hz), 2.73(3H, s), 3.21(2H, d, J=9Hz), 5.25(4H, s), 5.25 and 5.43(2H, ABq, J=14Hz), 7.50, 7.54 and 7.62(each 2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)
	HE	H	H		UVλ H ₂ O max nm: 297
9	PNZE	PNZ	PNB		IR _ν Nujol (cm ⁻¹): 1770, 1740, 1700, 1510, 1340, 1255 NMR. δ (CDCℓ ₃): 1.08(3H, d, J=6.5Hz), 1.11(3H, d, J=6.5Hz), 1.48(3H, d, J=6Hz), 3.18(2H, br.d, J=9Hz), 5.25(4H, s), 5.26 and 5.44(2H, ABq, J=14Hz), 7.50, 7.54 and 7.62(each 2H, J=9Hz), 8.20(6H, d, J=8.5Hz)
	HE	H	H		UVλ H ₂ O max nm: 296

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					IR ν_{max} Nujol (cm ⁻¹): 3275, 1782, 1740, 1700, 1650, 1515, 1340, 1260
	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}=\text{CH}_2 \\ \diagup \quad \diagdown \\ \text{N} \quad \text{H} \end{array}$	NMR δ (CDCl ₃): 1.48(3H, d, J=6.5Hz), 3.18(2H, br, d, J=9Hz), 5.24(4H, s), 5.25 and 5.45(2H, ABq, J=14Hz), 7.50, 7.53 and 7.62(each 2H, d, J=8.5Hz), 8.19(6H, d, J=8.5Hz)
10	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_3 \\ \diagup \quad \diagdown \\ \text{N} \quad \text{H} \end{array}$	NMR δ (D ₂ O): 1.0(3H, t, J=7.5Hz), 1.23(3H, d, J=7Hz)
					UV λ_{max} H ₂ O nm: 298
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}=\text{CH}_2 \\ \diagup \quad \diagdown \\ \text{N} \quad \text{H} \end{array}$	NMR δ (D ₂ O): 1.27(3H, d, J=7Hz), 5.68(3H, m)
					UV λ_{max} H ₂ O nm: 298

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
11	PNZE	PNZ	PNB	$\begin{array}{c} \text{C}_2\text{H}_5 \\ \diagdown \\ \text{-N-} \\ \diagup \\ \text{C}_2\text{H}_5 \end{array}$	$\text{IR}_{\text{neat}} (\text{cm}^{-1})_{\text{max}}: 1780, 1750, 1710, 1650, 1525, 1440, 1350, 1262$ $\text{NMR}_{\delta} (\text{CDCl}_3): 1.06(3\text{H}, \text{t}, \text{J}=7\text{Hz}), 1.27(3\text{H}, \text{t}, \text{J}=7\text{Hz}), 1.49(3\text{H}, \text{d}, \text{J}=6\text{Hz}), 5.24(4\text{H}, \text{s}), 5.25 \text{ and } 5.46(2\text{H}, \text{ABq}, \text{J}=14\text{Hz}), 7.46, 7.50 \text{ and } 7.63(\text{each } 2\text{H}, \text{d}, \text{J}=8.5\text{Hz}), 8.20(6\text{H}, \text{d}, \text{J}=8.5\text{Hz})$
12	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_3 \\ \diagdown \\ \text{-N-} \\ \diagup \\ \text{n-C}_4\text{H}_9 \end{array}$	$\text{IR}_{\text{CHCl}_3} (\text{cm}^{-1})_{\text{max}}: 1780, 1746, 1708, 1656, 1610, 1525, 1350, 1260$ $\text{NMR}_{\delta} (\text{CDCl}_3): 1.48(3\text{H}, \text{d}, \text{J}=6\text{Hz}), 5.27(4\text{H}, \text{s}), 8.20(6\text{H}, \text{d}, \text{J}=9\text{Hz})$


Example No.	R ₁	R ₂	R ₃	Y	Spectral Data	
13	PNZE	H	PNB	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{H} \end{array}$	IR ν _{max} Nujol (cm ⁻¹): 1770, 1735, 1640, 1510, 1340, 1250	
					NMR δ (CDCl ₃): 1.49(3H, d, J=6.5Hz), 4.42(2H, d, J=7.0Hz), 5.25(4H, s), 5.27 and 5.43(2H, ABq, J=14Hz), 7.27(5H, s), 7.54, 7.62, 8.21 and 8.22(each 2H, d, J=8.5Hz)	
14	HE	H	H	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{H} \end{array}$	UV λ _{max} ^{H₂O} nm: 297	
					IR ν _{max} ^{neat} (cm ⁻¹): 1780, 1750, 1715, 1660, 1525, 1442, 1350, 1265, 1122	
14	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{CH}_3 \end{array}$	NMR δ (CDCl ₃): 1.48(3H, d, J=6.5Hz), 2.92(3H, s), 4.56(2H, d, J=5Hz), 5.25(4H, s), 8.19(6H, d, J=9Hz)	
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{CH}_3 \end{array}$	UV λ _{max} ^{H₂O} nm: 297	

Example
No.

R₁ R₂ R₃

Y

Spectral Data




Nujol (cm⁻¹): 1790, 1745, 1714, 1652, 1605, 1520,
IR_{max} 1347

m.p. 179-182°C (dec.)

UV_{max} ^{H₂O} nm: 299, 266, 260

15

KBr (cm⁻¹): 1745, 1590, 1490, 1210, 1090, 910



HE H H

NMR_δ (D₂O):

1.26(3H, d, J=6.3Hz), 1.99(1H, m),
2.80(1H, m), 3.36(1H, dd, J=2.7 and
6.0Hz), 3.58(1H, dd, J=7.0 and
12.0Hz), 3.86(1H, m), 4.51(2H, d,
J=4.4Hz), 7.82(1H, dt, J=1.8 and
7.7Hz), 8.42(1H, m)

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data	
16	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2 \\ \\ \text{N} \end{array}$	IR ν _{max} (cm ⁻¹): 1775, 1745, 1700, 1660(sh), 1515, 1345, 1260 NMR δ (CDCl ₃): 1.47(3H, d, J=6.5Hz), 2.24(3H, s), 2.27(3H, s), 5.25(4H, s), 7.49, 7.53 and 7.62(each 2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)	
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2 \\ \\ \text{N} \end{array}$	UV λ _{max} ^{H₂O} nm: 297	
17	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2 \\ \\ \text{N} \end{array}$	IR ν _{max} (cm ⁻¹): 1770, 1745, 1700, 1650, 1512, 1342, 1257 NMR δ (CDCl ₃): 1.49(3H, d, J=6.0Hz), 2.24(3H, s), 2.30(6H, s), 5.25(4H, s), 5.27 and 5.45(2H, ABq, J=13.5Hz), 7.54(4H, d, J=8.5Hz), 7.63(2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)	
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2 \\ \\ \text{N} \end{array}$	UV λ _{max} ^{H₂O} nm: 298	

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
18	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{OH} \\ \\ \text{---N---} \\ \\ \text{H} \end{array}$	<p>IR ν_{max} (neat) (cm⁻¹): 3350, 1770, 1740, 1695, 1510, 1340, 1250</p> <p>NMR δ (CDCl₃): 1.48(3H, d, J=6Hz), 5.25(4H, s), 5.18 and 5.43(2H, ABq, J=14Hz), 7.49, 7.53 and 7.61(each 2H, d, J=8.5Hz), 8.18(6H, d, J=8.5Hz)</p> <p>UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 298</p>
19	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{OH} \\ \\ \text{---N---} \\ \\ \text{CH}_3 \end{array}$	<p>IR ν_{max} (neat) (cm⁻¹): 3400, 1778, 1745, 1700, 1650, 1520, 1345, 1260, 1120</p> <p>NMR δ (CDCl₃): 1.48(3H, d, J=6.5Hz), 3.00(3H, s), 5.20(2H, s), 5.25(2H, s), 5.25 and 5.45(2H, ABq, J=13.5Hz), 7.49, 7.51 and 7.63(each 2H, d, J=8.5Hz), 8.19(4H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)</p> <p>UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 297</p>

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
20	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{COOPNB} \\ \\ \text{N} \end{array}$	IR ν _{max} (neat) (cm ⁻¹): 1770, 1730, 1695, 1650, 1600, 1505, 1340 NMR δ (CDCl ₃): 1.48(3H, d, J=6.5Hz), 5.25(4H, s), 7.62(2H, d, J=8.6Hz), 8.20(6H, d, J=8.6Hz)
21	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{COOH} \\ \\ \text{N} \end{array}$	IR ν _{max} (H ₂ O): 297 IR ν _{max} (Nujol) (cm ⁻¹): 1795, 1747, 1712, 1640, 1608, 1517, 1350, 1275 m.p. 167-169°C (dec.) IR ν _{max} (H ₂ O): 300 IR ν _{max} (KBr) (cm ⁻¹): 1752, 1650, 1590, 1388, 1255, 1150 NMR δ (D ₂ O): 1.26(3H, d, J=6.3Hz), 2.71(3H, s), 2.93(1H, q, J=7.4Hz), 3.88(2H, s)

Example
No.

R_1 R_2 R_3 Y Spectral Data

PNZE PNZ PNB $\begin{array}{c} \text{CH}_2\text{CON}(\text{CH}_3)_2 \\ | \\ \text{-N-} \end{array}$ IR ν Nujol (cm^{-1}): 1800, 1750, 1707, 1675, 1650, 1610, 1520, 1350, 1280
m.p. 196-199°C (dec.)

UV λ H_2O nm: 299
max

22

HE H H $\begin{array}{c} \text{CH}_2\text{CON}(\text{CH}_3)_2 \\ | \\ \text{-N-} \end{array}$ IR ν KBr (cm^{-1}): 1750, 1640, 1590, 1380, 1250, 1145
max

NMR δ (D_2O): 1.26(3H, d, $J=6.3\text{Hz}$), 2.92(3H, s), 3.03(3H, s), 3.19(2H, dd, $J=6.3$ and 9.2Hz), 3.51(1H, dd, $J=7.4$ and 12Hz), 4.12(2H, s)

PNZE PNZ PNB $\begin{array}{c} \text{CH}_3 \\ | \\ \text{CHCONH}_2 \\ | \\ \text{-N-} \end{array}$ IR ν Nujol (cm^{-1}): 1795, 1750, 1700, 1680, 1655, 1610, 1525, 1350
max

m.p. 168-170°C (dec.)

23

HE H H $\begin{array}{c} \text{CH}_3 \\ | \\ \text{CHCONH}_2 \\ | \\ \text{-N-} \end{array}$ IR ν KBr (cm^{-1}): 1745, 1665, 1590, 1390, 1180, 1037
max
UV λ H_2O nm: 300
max

0126587


140

Example
No.

R₁ R₂ R₃

Y

Spectral Data




IR ν_{max} (cm⁻¹): 1780, 1745, 1705, 1640, 1605, 1520, 1346

m.p. 172-175°C

NMR δ (D₆-DMCO): 1.12(3H, d, J=7Hz), 1.34(3H, d, J=6.4Hz), 2.79(3H, s), 2.94(3H, s), 5.30(2H, s), 8.20(6H, d, J=8.8Hz)

25

UV λ_{max}^{H₂O} nm: 300



IR ν_{max}^{KBr} (cm⁻¹): 1755, 1630, 1590, 1390, 1250, 1120

NMR δ (D₂O): 1.26(3H, d, J=6.3Hz), 1.31(3H, d, J=6.9Hz), 2.92(3H, s), 3.13(3H, s)

0126587

- 142 -



0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CONH}_2 \\ \diagup \quad \diagdown \\ \text{N} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array}$	$\text{IR}_{\text{max}}^{\text{CHCl}_3} (\text{cm}^{-1}): 1783, 1746, 1705, 1680, 1608, 1524, 1345$ $\text{NMR}_{\delta} (\text{CDCl}_3): 1.48(3\text{H}, \text{d}, J=6.4\text{Hz}), 3.19(3\text{H}, \text{s}), 5.17(2\text{H}, \text{s}), 5.24(2\text{H}, \text{s}), 8.19(6\text{H}, \text{d}, J=8.6\text{Hz})$
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CONH}_2 \\ \diagup \quad \diagdown \\ \text{N} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array}$	$\text{IR}_{\text{max}}^{\text{KBr}} (\text{cm}^{-1}): 1750, 1654, 1590, 1395, 1250, 1060$ $\text{NMR}_{\delta} (\text{D}_2\text{O}): 1.26(3\text{H}, \text{d}, J=6.3\text{Hz}), 2.95(3\text{H}, \text{s}), 3.21(2\text{H}, \text{dd}, J=2.2 \text{ and } 9.0\text{Hz}), 3.38(1\text{H}, \text{dd}, J=2.2 \text{ and } 5.5\text{Hz})$

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNE	$ \begin{array}{c} \text{CH}_2\text{CONHCH}_3 \\ \diagup \quad \diagdown \\ \text{---N---} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array} $	IR ν_{max} CHCl_3 (cm^{-1}): 1778, 1743, 1685, 1660, 1605, 1520, 1340 NMR δ (CDCl_3): 1.48(3H, d, J=6.2Hz), 2.72(3H, d, J=5Hz), 3.19(3H, s), 5.22(2H, s), 5.25(2H, s), 8.22(6H, d, J=8.8Hz)
27	HE	H	H	$ \begin{array}{c} \text{CH}_2\text{CONHCH}_3 \\ \diagup \quad \diagdown \\ \text{---N---} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array} $	UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 300 IR $\nu_{\text{max}}^{\text{KBr}}$ (cm^{-1}): 1750, 1640, 1585, 1382, 1250, 1125 NMR δ (D_2O): 1.26(3H, d, J=6.3Hz), 2.73(3H, s), 3.09(3H, s), 3.39(1H, q, J=2.6Hz)

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB	$ \begin{array}{c} \text{CH}_2\text{CON}(\text{CH}_3)_2 \\ \diagup \quad \diagdown \\ \text{-N-} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array} $	IR ν _{neat} (cm ⁻¹): 1778, 1745, 1705, 1650, 1605, 1520, 1345 NMR δ (CDCl ₃): 1.49(3H, d, J=6.2Hz), 2.93(3H, s), 2.99(3H, s), 3.10 and 3.15(3H, s), 5.25(4H, s), 8.21(6H, d, J=8.4Hz)
	HE	H	H	$ \begin{array}{c} \text{CH}_2\text{CON}(\text{CH}_3)_2 \\ \diagup \quad \diagdown \\ \text{-N-} \\ \diagdown \quad \diagup \\ \text{CH}_3 \end{array} $	UV λ _{H₂O} nm: 297 IR ν _{KBr} (cm ⁻¹): 1760, 1650, 1500, 1380, 1240, 1130

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
29	PNZE	PNZ	PNB		<p>IR ν_{max} (neat): 1778, 1750, 1705, 1650, 1518, 1430, 1345, 1258</p> <p>NMR δ (CDCl₃): 1.49(3H, d, J=6.5Hz), 2.25(3H, s), 2.31(4H, s), 5.25(4H, s), 5.21 and 5.46(2H, ABq, J=13.5Hz), 7.53(4H, d, J=8.5Hz), 7.62(2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)</p> <p>UV λ_{H₂O} max nm: 298</p>
30	PNZE	PNZ	PNB		<p>IR ν_{max} (neat): 1780, 1750, 1710, 1655, 1520, 1350, 1255, 1115</p> <p>NMR δ (CDCl₃): 1.48(3H, d, J=6.5Hz), 3.58 and 3.67(each 4H, s), 5.25(4H, s), 5.26 and 5.45(2H, ABq, J=14Hz), 7.53(4H, d, J=9Hz), 7.62(2H, d, J=9Hz), 8.19(6H, d, J=9Hz)</p> <p>UV λ_{H₂O} max nm: 298</p>

Example
No.

R₁

R₂

R₃

Y

Spectral Data

IRν_{max} CHCl₃ (cm⁻¹): 1780, 1740, 1705, 1655, 1610, 1520, 1345

NMRδ (CDC 3): 1.47(3H, d, J=6Hz), 5.22(4H, s), 8.13(6H, d, J=8Hz)

UVλ_{max}^{H₂O} nm: 298


IRν_{max} KBr (cm⁻¹): 1750, 1625, 1595, 1396, 1248, 1090

IRν_{max} neat (cm⁻¹): 1780, 1740, 1700, 1590, 1520, 1340, 1255


NMRδ (CDCℓ₃): 1.49(3H, d, J=6.6Hz), 5.26(4H, s), 5.35(2H, ABq, J=14.5Hz), 7.46(2H, d, J=5.5Hz), 8.48(2H, d, J=5.5Hz)

UVλ_{max}^{H₂O} nm: 245, 300

IRν (cm⁻¹): 1745, 1690, 1590, 1507, 1383, 1285



PNZE PNZ PNB





HE H H



PNZE PNZ PNB



HE H H

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB		IR _{Nujol} (cm ⁻¹): 1785, 1745, 1705, 1605, 1520, 1350 max m.p. 181-183°C (dec.)
					UV _λ H ₂ O nm: 296, 276, 231 max
33	HE	H	H		IR _{KBr} (cm ⁻¹): 1750, 1690, 1595, 1435, 1385, 1240, max 1090 NMR δ (D ₂ O): 1.26(3H, d, J=6.3Hz), 1.95(1H, m), 3.20(1H, dd, J=4.0 and 9.0Hz), 3.37(1H, dd, J=2.6 and 6.1Hz), 8.32(1H, dd, J=1.3 and 5.0Hz), 8.60(1H, d, J=2.2Hz)

0126587

- 148 -

Example


No.

R₁ R₂ R₃

Y

Spectral Data

IR ν_{max} Nujol (cm⁻¹): 1790, 1745, 1705, 1670, 1605, 1515, 1345
 m.p. 189-191°C (dec.)




PNZE PNZ PNB

UV λ_{max} H₂O nm: 298, 286, 237

IR ν_{max} KBr (cm⁻¹): 1750, 1680, 1590, 1480, 1390, 1245, 1090

NMR δ (D₂O): 1.26(3H, d, J=6.3Hz), 1.95(1H, m), 3.20(1H, dd, J=4.0 and 9.0Hz), 3.37(1H, dd, J=2.6 and 6.1Hz), 8.32(1H, dd, J=1.3 and 4.9Hz), 8.60(1H, d, J=2.2Hz)




HE H H

34

IR ν_{max} neat (cm⁻¹): 1775, 1750, 1705, 1640, 1520, 1345, 1255, 1110


NMR δ (CDCl₃): 1.48(3H, d, J=6.5Hz), 5.24(4H, s), 5.23 and 5.44(2H, ABq, J=14Hz), 8.19(6H, d, J=8.5Hz)



PNZE PNZ PNB



35

UV λ_{max} H₂O nm: 297







HE H H



0126587



Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					IR _ν ^{neat} (cm ⁻¹): 1782, 1750, 1710, 1660, 1522, 1445, 1355, 1270, 1140
					NMR δ (CDC 3): 1.48(3H, d, J=6Hz), 5.26(4H, s), 5.18 and 5.42(2H, ABq, J=14Hz), 7.50(2H, d, J=8.5Hz), 7.53(2H, d, J=8.5Hz), 7.62(2H, d, J=8.5Hz), 8.19(6H, d, J=8.5Hz)
					
					UVλ _{H₂O} ^{max} nm: 298
					IR _ν ^{KBr} (cm ⁻¹): 1755, 1630, 1600, 1440, 1382, 1240
					
					NMR δ (D ₂ O): 1.26(3H, d, J=6.3Hz), 2.34(2H, m), 3.36(1H, dd, J=3.4 and 5.5Hz), 3.84(1H, m)

0126587



Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 1780, 1740(sh), 1710, 1605, 1520, IR _{max} 1340
					NMRδ (CDCl ₃): 1.48(3H, d, J=6.4Hz), 5.25(4H, s), 6.32(2H, d, J=2Hz), 8.16(6H, d, J=8.8Hz)
					UVλ _{H₂O} nm: 297, 241
					IR _{KBr} (cm ⁻¹): 1750, 1720, 1590, 1470, 1390, 1280
					NMRδ (D ₂ O): 1.26(3H, d, J=6.2Hz), 2.12(2H, m), 6.44(2H, t, J=2.2Hz), 7.39(2H, t, J=2.2Hz)



Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 1780, 1750, 1700, 1650(sh), 1610, IRν _{max} 1525, 1350
					NMRδ (CDCl ₃): 1.47(3H, d, J=6Hz), 5.22(4H, s), 8.12(6H, d, J=8.5Hz)
					UVλ _{H₂O} nm: 298
	HE	H	H		IRν _{KBr} (cm ⁻¹): 1750, 1650, 1600, 1440, 1395

Example No.	R ₁ R ₂ R ₃			Y	Spectral Data
	R ₁	R ₂	R ₃		
39	PNZE	PNZ	PNB		<p>IR_νCHCl₃ (cm⁻¹): 1783, 1750, 1715, 1660, 1615, 1530, 1350</p> <p>NMRδ (CDCl₃): 1.48(3H, d, J=5.9Hz), 5.25(4H, s), 8.15(6H, d, J=8.6Hz)</p> <p>UVλ_{max}^{H₂O} nm: 298</p>
	HE	H	H'		<p>IR_νKBr (cm⁻¹): 1750, 1630, 1590, 1460, 1380, 1240, 1090</p> <p>NMRδ (D₂O): 1.27(3H, d, J=6.3Hz), 3.19(1H, dd, J=2.9 and 9.2Hz), 3.39(1H, dd, J=2.6 and 6.0Hz)</p>

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB		<p>IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm⁻¹): 1780, 1740, 1708, 1640, 1605, 1520, 1345</p> <p>NMR δ (CDCl₃): 1.50(3H, d, J=6.2Hz), 5.28(4H, s), 8.19(6H, d, J=8.1Hz)</p> <p>UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 297</p> <p>IR $\nu_{\text{max}}^{\text{KBr}}$ (cm⁻¹): 1760, 1635, 1600, 1450, 1380</p> <p>NMR δ (D₂O): 1.27(3H, d, J=6.3Hz), 3.19(1H, dd, J=2.9 and 9.1Hz), 3.39(1H, dd, J=2.7 and 6.0Hz), 3.55(2H, d, J=4.0Hz), 3.69(1H, dd, J=2.0 and 4.3Hz)</p>
	HE	H	H		

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB		<p>IR ν_{max} CHCl₃ (cm⁻¹): 1780, 1750, 1705, 1635, 1605, 1520, 1345</p> <p>NMR δ (CDCl₃): 1.49(3H, d, J=6.4Hz), 5.26(4H, s), 8.20(6H, d, J=8.8Hz)</p> <p>UV λ_{max} H₂O nm: 298</p> <p>IR ν_{max} KBr (cm⁻¹): 1755, 1625, 1440, 1380, 1240</p> <p>NMR δ (D₂O): 1.23(3H, d, J=6.5Hz), 1.25(3H, d, J=6Hz), 1.31(3H, d, J=7Hz)</p>
	HE	H	H		

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
42	PNZE	PNZ	PNB		IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm ⁻¹): 1785, 1746, 1705, 1657, 1610, 1525, 1345 NMR δ (CDCl ₃): 1.47(3H, d, J=6.2Hz), 5.25(4H, s), 8.16(6H, d, J=8.6Hz)
	HE	H	H		IR $\nu_{\text{max}}^{\text{H}_2\text{O}}$ (cm ⁻¹): 1750, 1655(sh), 1635, 1610(sh), 1380, 1220 NMR δ (D ₂ O): 1.26(3H, d, J=6.3Hz)

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	PNZE	PNZ	PNB	$\begin{array}{c} \text{N(CH}_3\text{)}_2 \\ \\ \text{-N=} \\ \\ \text{N(CH}_3\text{)}_2 \end{array}$	CHCl_3 (cm ⁻¹): 1780, 1745, 1702, 1603, 1520, 1345 $\text{IR } \nu_{\text{max}}$ $\text{NMR } \delta$ (CDCl ₃): 1.48(3H, d, J=6Hz), 2.85(6H, s), 2.93(6H, s), 5.26(4H, s)
	HE	H	H	$\begin{array}{c} \text{N(CH}_3\text{)}_2 \\ \\ \text{-N=} \\ \\ \text{N(CH}_3\text{)}_2 \end{array}$	H_2O nm: 299, 229 KBr (cm ⁻¹): 1750, 1690, 1590, 1420, 1285, 1130 $\text{IR } \nu_{\text{max}}$ $\text{NMR } \delta$ (D ₂ O): 1.26(3H, d, J=6.3Hz), 1.91(1H, m), 2.60(1H, m), 3.08(6H, s), 3.16(6H, s), 3.40(1H, dd, J=2.7 and 6.0Hz), 4.37(1H, dd, J=6.0 and 9.5Hz)

Example
No.

R₁

R₂

R₃


Y

Spectral Data

PNZE

PNZ

PNB



IR_{max}^{CHCl₃} (cm⁻¹): 1780, 1740, 1705, 1605, 1523, 1345

NMR_δ (CDCl₃): 1.47(3H, d, J=6.8Hz), 5.25(4H, s)

44


UVλ_{max}^{H₂O} nm:

207, 299

HE

H

H



IR_{max}^{KBr} (cm⁻¹): 1750, 1640, 1590, 1545, 1385, 1040

NMR_δ (D₂O): 1.25(3H, d, J=6.6Hz), 1.85(1H, m)

0126587

Example
No.

Example No.	R ₁ R ₂ R ₃			Y	Spectral Data	
	R ₁	R ₂	R ₃			
45	PNZE	PNZ	PNB	-OPNB	IR ν_{\max}^{neat} (cm ⁻¹):	1775(sh), 1750, 1710, 1520, 1350, 1265
					NMR δ (CDC ℓ_3):	1.48(3H, d, J=6.5Hz), 4.70(1H, dd, J=6 and 8.5Hz), 5.25(4H, s), 5.46(1H, d, J=14Hz), 7.53(4H, d, J=8.5Hz), 7.62(4H, d, J=8.5Hz), 8.18(4H, d, J=8.5Hz), 8.21(4H, d, J=8.5Hz)
	HE	H	H	-OH	UV $\lambda_{\max}^{\text{H}_2\text{O}}$ nm:	294
46	PNZE	PNZ	PNB	-OCH ₃	IR $\nu_{\max}^{\text{CHCl}_3}$ (cm ⁻¹):	1787, 1753, 1716, 1614, 1530, 1431, 1410, 1355, 1268, 1138, 1116
					NMR δ (CDC ℓ_3):	1.48(3H, d, J=6Hz), 1.83-2.42(1H, m), 2.50-3.02(1H, m), 3.17-4.53(8H, m), 3.70 and 3.73(3H, s), 5.02-5.28(2H, m), 5.27(4H, s), 5.47(1H, d, J=14Hz), 7.53(4H, d, J=9Hz), 7.63(2H, d, J=9Hz), 8.21(6H, d, J=9Hz)
	HE	H	H	-OCH ₃	UV $\lambda_{\max}^{\text{H}_2\text{O}}$ nm:	300
					IR ν_{\max}^{KBr} (cm ⁻¹):	1735, 1595, 1488, 1388, 1245, 1090

Example
No.R₁ R₂ R₃

Y

Spectral Data

Nujol (cm⁻¹): 1782, 1750, 1705, 1620, 1520, 1350
 IRν_{max}
 m.p. 184-187°C (dec.)

47

-NHNH₂

PNZE PNZ PNB

H₂O
 UVλ_{max} nm: 299

-NHNH₂

HE H H

KBr (cm⁻¹): 1750, 1720, 1590, 1390, 1245, 1120
 IRν_{max}

160

Nujol (cm⁻¹): 1785, 1750, 1715, 1668, 1608, 1520,
 IRν_{max} 1345

m.p. 187-189°C (dec.)

-NHN(CH₃)₂

PNZE PNZ PNB

H₂O
 UVλ_{max} nm: 300

48

KBr (cm⁻¹): 1750, 1690, 1595, 1390, 1175, 1020
 IRν_{max}

-NHN(CH₃)₂

HE H H

NMRδ (D₂O): 1.26(3H, d, J=6.4Hz), 2.60(6H, s),
 3.18(1H, dd, J=6.0 and 9.1Hz),
 3.39(1H, dd, J=2.6 and 6.0Hz)

0126587

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 1784, 1750, 1714, 1608, 1524, 1432, 1404, 1378, 1348, 1265, 1197, 1132, 1113
	PNZE	PNZ	PNB	-OC ₂ H ₅	NMR δ (CDCl ₃): 1.13-1.36(3H, m), 1.48(3H, d, J=6Hz), 1.83-2.36(1H, m), 2.56-3.06(1H, m), 3.19-4.59(10H, m), 4.89-5.36(2H, m), 5.27(4H, s), 5.47(1H, d, J=14Hz), 7.54(4H, d, J=8.5Hz), 7.63(2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)
					UV λ _{max} ^{H₂O} nm: 298
	HE	H	H	-OC ₂ H ₅	IR ν _{max} ^{KBr} (cm ⁻¹): 1743, 1597, 1380, 1240, 1130
					NMR δ (D ₂ O): 1.25(3H, d, J=6Hz), 1.27(3H, t, J=7Hz), 2.29(1H, m), 4.29(2H, q, J=7Hz)

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
50	PNZE	PNZ	PNB	-NHOPNB	Nujol (cm ⁻¹): 1790, 1750, 1715, 1670, 1602, 1515, IR ν _{max} 1340 m.p. 149-152°C (dec.)
	HE	H	H	-NHOH	H ₂ O UV λ _{max} nm: 300
					KBr (cm ⁻¹): 1750, 1680, 1600, 1400, 1120 IR ν _{max}
	PNZE	PNZ	PNB	-NH ₃ CH ₃	Nujol (cm ⁻¹): 1787, 1745, 1710, 1665, 1605, 1520, IR ν _{max} 1345 m.p. 188-189.5°C (dec.)
51					H ₂ O UV λ _{max} nm: 299
	HE	H	H	-NH ₃ CH ₃	KBr (cm ⁻¹): 1745, 1680, 1600, 1440, 1390, 1245, IR ν _{max} 1050
					NMR δ (D ₂ O): 3.70(3H, s)

Example
No.

R₁

R₂

R₃

Y

Spectral Data


IR ν_{max} CHCl₃ (cm⁻¹): 1773, 1743, 1705, 1663, 1605, 1523, 1345, 1255

NMR δ (CDCl₃): 1.49(3H, d, J=6.5Hz), 5.23(2H, s), 5.26(2H, s), 8.19(6H, d, J=8.8Hz)


UV λ_{max} H₂O nm: 298

IR ν_{max} KBr (cm⁻¹): 1763, 1660, 1590, 1380, 1240, 1060

NMR δ (D₂O): 1.26(3H, d, J=6.6Hz), 2.50(3H, s), 2.52(3H, s), 2.92(3H, s), 3.18(2H, q, J=4.3Hz)



PNZE PNZ PNB



HE H H

Example
No.

R₁

R₂

R₃

Y

Spectral Data

IR ν_{max}^{neat} (cm⁻¹): 1780, 1750, 1710, 1605, 1525, 1350,
1260



NMR δ (CDCl₃): 1.49(3H, d, J=6.4Hz), 5.25(4H, s),
5.36(2H, ABq, J=13.6Hz), 7.53(4H, d,
J=8.8Hz), 7.62(2H, d, J=8.8Hz),
8.21(6H, d, J=8.8Hz)

UV λ_{max}^{H₂O} nm: 300


IR ν_{max}^{KBr} (cm⁻¹): 1735, 1595, 1396, 1255, 1215, 1043



0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					IR ν _{max} (cm ⁻¹): 1780, 1745, 1705, 1645, 1520, 1440, 1350, 1262
	PNZE	PNZ	PNB		NMR δ (CDC ₂ Cl ₂): 1.49(3H, d, J=6.5Hz), 5.26(4H, s), 5.24 and 5.43(2H, ABq, J=14Hz), 7.44(2H, d, J=9Hz), 7.48(2H, d, J=9Hz), 7.68(2H, d, J=9Hz), 8.19(6H, d, J=9Hz)
	HE	H	H		UV λ _{max} ^{H₂O} nm: 298 NMR δ (D ₂ O): 1.27(3H, d, J=6Hz), 1.83(4H, t, J=7Hz), 1.94-2.09(1H, m), 2.42(4H, t, J=7Hz), 2.77-2.92(1H, m), 3.11-3.42(5H, m), 3.81-3.99(1H, m), 4.14-4.29(2H, m)

0126587



Example
No.

R₁ R₃

A


Spectral Data

IR ν_{max} (cm⁻¹): 1775, 1745, 1700, 1520, 1345, 1260, 1130


NMR δ (CDCl₃): 1.48(3H, d, J=6.5Hz), 3.22(2H, br, d, J=9.0Hz), 5.26(4H, s), 5.25 and 5.46(2H, ABq, J=14Hz), 7.50, 7.54 and 7.60(each 2H, d, J=9.0Hz), 8.18(4H, d, J=9.0Hz), 8.21(2H, d, J=9.0Hz)

[α]_D²⁹ +37.3° (c=0.244, acetone)



UV λ_{max}^{H₂O} nm: 298







PNZE PNZ




HE H

Example No.	R ₁	R ₃	A	Spectral Data
56	PNZE	PNZ		IR ν_{max} (neat, cm^{-1}): 1780, 1745, 1700, 1610, 1520, 1400, 1350, 1260, 1120 NMR δ (CDCl_3): 1.48(3H, d, J=6Hz), 3.19(2H, d, J=9Hz), 3.44(1H, dd, J=2.5 and 7.5Hz), 5.25(4H, s), 5.23 and 5.42(2H, ABq, J=14Hz), 7.47, 7.52 and 7.60(each 2H, d, J=8.5Hz), 8.16(4H, d, J=8.5Hz), 8.19(2H, d, J=8.5Hz)
56	HE	H		$[\alpha]_D^{32} +57.6^\circ$ (c=0.279, acetone) UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 297

0126587

Example No.	R ₁	R ₃	A	Spectral Data
57	PNZE	PNB		IR ν _{max} (cm ⁻¹): 1775, 1750, 1700, 1520, 1345, 1260, 1180 NMR δ (CDCl ₃): 1.48(3H, d, J=6.5Hz), 3.26(2H, br, d, J=9.0Hz), 5.25(4H, s), 5.18 and 5.46(2H, ABq, J=14Hz), 7.49, 7.53 and 7.62(each 2H, d, J=8.5Hz), 8.17(4H, d, J=8.5Hz), 8.19(2H, d, J=8.5Hz)
				$[\alpha]_D^{25} +43.7^\circ$ (c=0.353, acetone)
	HE	H		IR ν _{max} (cm ⁻¹): 1750, 1705, 1645, 1610, 1525, 1440, 1350, 1265
58	PNZE	PNB		IR ν _{max} (cm ⁻¹): 1750, 1705, 1645, 1610, 1525, 1440, 1350, 1265
	HE	H		



Example
No.

R₁

R₂

R₃

Y

Spectral Data

- 169 -

CHCl₃ (cm⁻¹): 1775, 1700, 1607, 1520, 1395, 1345,
IR_{max} 1105

HE PNZ PNB

-NH₂

NMR δ (CDCl₃):

1.36(3H, d, J=6.0Hz), 1.37(3H, d,
J=7.0Hz), 5.24(2H, s), 5.35(2H,
ABq, J=13.5Hz), 7.50(2H, d,
J=8.8Hz), 7.64(2H, d, J=8.8Hz),
8.22(4H, d, J=8.8Hz)

59

UVλ_{max}^{H₂O} nm: 295

HE H H

-NH₂

IR_{max}^{KBr} (cm⁻¹): 1750, 1660(sh), 1600, 1380, 1240

0126587

Example
No.

R₁

R₂

R₃

Y

Spectral Data


IR_{max}^{CHCl₃} (cm⁻¹): 1770, 1695, 1650, 1520, 1340

NMRδ (CDCl₃):

1.34(3H, d, J=6.15Hz), 1.36(3H, d, J=8.0Hz), 3.00(3H, s), 5.20(2H, s), 5.36(2H, ABq, J=14.0Hz), 7.47(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.20(2H, d, J=8.8Hz)

UVλ_{max}^{H₂O} nm: 289

IR_{max}^{KBr} (cm⁻¹): 1750, 1630, 1605, 1375, 1240



Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
	HE	PNZ	PNB	NHCH ₂ CONH ₂	IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm ⁻¹): 3380, 1770, 1725(sh), 1700, 1680, 1605, 1520, 1342, 1250, 1102 NMR δ (CDCl ₃): 5.30(2H, s), 5.31(2H, ABq, J=13.8Hz), 7.48(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.21(4H, d, J=8.8Hz)
					UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 295
61	HE	H	H	NHCH ₂ CONH ₂	IR $\nu_{\text{max}}^{\text{KBr}}$ (cm ⁻¹): 1750, 1670, 1600, 1390, 1245 NMR δ (D ₂ O): 1.26(3H, d, J=6.5Hz), 1.28(3H, d, J=8Hz), 3.92(2H, s)

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 3480, 3350, 1773, 1678, 1604, 1525, IRν _{max} 1345, 1310
62	HE	PNZ	PNB	NCH ₂ CONH ₂ Me	NMRδ (CDCl ₃): 1.34(3H, d, J=6.2Hz), 1.37(3H, d, J=7.0Hz), 3.20(3H, s), 5.18(2H, s), 5.36(2H, ABq, J=13.4Hz), 7.46(2H, d, J=8.8Hz), 7.63(2H, d, J=8.8Hz), 8.20(2H, d, J=8.8Hz), 8.21(2H, d, J=8.8Hz)
	HE	H	H	NCH ₂ CONH ₂ Me	UVλ _{H₂O} _{max} nm: 292 IRν _{KBr} _{max} (cm ⁻¹): 1752, 1645, 1600, 1385, 1245

Example
No.

R₁ R₂ R₃

Y

Spectral Data

IR ν_{max} CHCl_3 (cm^{-1}): 3420, 1772, 1705, 1660, 1623, 1606, 1526, 1440, 1345

$[\alpha]_D^{25} -45^\circ$ ($c=0.11$, CHCl_3)



HE PNZ PNB

NMR δ (CDCl_3):

1.33(3H, d, $J=6.15\text{Hz}$), 1.37(3H, d, $J=6.8\text{Hz}$), 4.19(4H, br, s), 5.21(2H, s), 5.36(2H, ABq, $J=13.9\text{Hz}$), 5.84(2H, s), 7.40(2H, d, $J=8.6\text{Hz}$), 7.64(2H, d, $J=8.6\text{Hz}$), 8.14(2H, d, $J=8.6\text{Hz}$), 8.19(2H, d, $J=8.6\text{Hz}$)

UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 293





IR ν_{max} KBr (cm^{-1}): 1750, 1640, 1610, 1460, 1380



HE H H

NMR δ (D_2O): 1.25(3H, d, $J=6\text{Hz}$), 1.27(3H, d, $J=7.5\text{Hz}$), 5.85(2H, br, s)

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm ⁻¹): 1770, 1702, 1650, 1520, 1343, 1102
	HE	PNZ	PNB		NMR δ (CDCl ₃): 1.33(3H, d, J=6.15Hz), 1.37(3H, d, J=7.0Hz), 5.21(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.6Hz), 7.64(2H, d, J=8.6Hz), 8.20(4H, d, J=8.6Hz)
					UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 293
	HE	H	H		IR $\nu_{\text{max}}^{\text{KBr}}$ (cm ⁻¹): 1755, 1630(sh), 1610, 1442, 1383, 1240, 1110
					NMR δ (D ₂ O): 1.25(3H, d, J=6.5Hz), 1.28(3H, d, J=7Hz)

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
65	HE	PNZ	PNB		<p>IR, CHCl_3 (cm^{-1}): 3400, 1770, 1705, 1650, 1520, 1432, 1345, 1107</p> <p>NMRδ (CDCl_3): 1.35(3H, d, J=6.0Hz), 1.36(3H, d, J=7.0Hz), 5.20(2H, s), 5.36(2H, ABq, J=13.5Hz), 7.46(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.21(2H, d, J=8.8Hz)</p>
	HE	H	H		<p>UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 293</p> <p>IR, KBr (cm^{-1}): 1760, 1615, 1390, 1245, 1100</p>

Example
No.

R₁

R₂

R₃

Y

Spectral Data


IR ν_{max} CHCl_3 (cm^{-1}): 1770, 1705, 1656, 1525, 1345, 1112

NMR δ (CDCl_3):


1.35(3H, d, J=6.15Hz), 1.36(3H, d, J=7.0Hz), 5.22(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.0Hz), 7.64(2H, d, J=8.0Hz), 8.20(4H, d, J=8.0Hz)

UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 292



IR $\nu_{\text{max}}^{\text{KBr}}$ (cm^{-1}): 1760, 1630(sh), 1605, 1448, 1380, 1245, 1110



HE PNZ PNB




HE H H

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
67	HE	PNZ	PNB		IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm ⁻¹): 1772, 1710, 1650, 1520, 1435, 1400, 1340 NMR δ (CDCl ₃): 1.34(3H, d, J=6.0Hz), 1.35(3H, d, J=7.5Hz), 2.25(3H, s), 2.31(4H, s), 5.22(2H, s), 5.36(2H, ABq, J=14.1Hz), 7.49(2H, d, J=8.6Hz), 7.63(2H, d, J=8.6Hz), 8.20(4H, d, J=8.6Hz)
	HE	H	H		UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 291 IR $\nu_{\text{max}}^{\text{KBr}}$ (cm ⁻¹): 1755, 1620, 1442, 1380, 1250

0126587



Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
68	HE	PNZ	PNB	-OCH ₃	<p>IR ν_{max} CHCl₃ (cm⁻¹): 1775(sh), 1750(sh), 1710, 1605, 1522, 1345, 1107</p> <p>NMR δ (CDCℓ₃): 1.35(3H, d, J=6.4Hz), 1.36(3H, d, J=6.8Hz), 3.66 and 3.73(3H, each s), 5.24(2H, s), 5.36(2H, ABq, J=13.2Hz), 7.45(2H, d, J=8.5Hz), 7.65(2H, d, J=8.5Hz), 8.22(4H, d, J=8.5Hz)</p> <p>UV λ_{max}^{H₂O} nm: 296</p> <p>IR ν_{max}^{KBr} (cm⁻¹): 1735, 1602, 1390</p>
	HE	H	H	-OCH ₃	




L-trans

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 3400, 1770, 1708, 1652, 1604, 1523, IRV _{max} 1397, 1342
	HE	PNZ	PNB	-N(CH ₃) ₂	[α] _D ²⁵ -33° (c=0.10, CHCl ₃)
69					NMRδ (CDCl ₃): 1.34(3H, d, J=6.15Hz), 1.39(3H, d, J=7.0Hz), 2.97(3H, s), 2.91 and 3.12(3H, s), 5.21(2H, s), 5.35(2H, ABq, J=13.2Hz), 8.20(4H, d, J=8.6Hz)
	HE	H	H	-N(CH ₃) ₂	UVλ _{max} ^{H₂O} nm: 286
					IRV _{max} ^{KBr} (cm ⁻¹): 1750, 1630(sh), 1610, 1395, 1250

0126587

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
					CHCl ₃ (cm ⁻¹): 3400, 1775, 1707, 1642, 1608, 1526, IRν _{max} 1445, 1345
					[α] _D ²⁵ -33° (c=0.11, CHCl ₃)
	HE	PNZ	PNB		NMRδ (CDCl ₃): 1.33(3H, d, J=6.15Hz), 1.40(3H, d, J=6.8Hz), 5.20(2H, s), 5.35(2H, ABq, J=13.8Hz), 7.47(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.20(2H, d, J=8.8Hz)
70					- 180 -
					UVλ _{max} ^{H₂O} nm: 288
	HE	H	H		IRν _{max} ^{KBr} (cm ⁻¹): 1760, 1635(sh), 1610, 1450, 1380, 1240

0126587



D-trans

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
71	HE	PNZ	PNB	-N(CH ₃) ₂	<p>IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm⁻¹): 3400, 1770, 1700, 1650, 1605, 1520, 1400, 1120</p> <p>NMR δ (CDCl₃): 1.33(3H, d, J=6.15Hz), 1.39(3H, d, J=6.8Hz), 2.98(3H, s), 2.92 and 3.12(3H, each s), 5.22(2H, s), 5.36(2H, ABq, J=13.5Hz), 7.50(2H, d, J=8.6Hz), 7.64(2H, d, J=8.6Hz), 8.21(4H, d, J=8.6Hz)</p> <p>UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 291</p> <p>IR $\nu_{\text{max}}^{\text{KBr}}$ (cm⁻¹): 1755, 1630(sh), 1610, 1390, 1250</p>

0126587

Ex. mple
No.R₁R₂R₃

Y

Spectral Data

IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm⁻¹): 3420, 1775, 1710, 1660, 1621, 1528,
1420, 1405, 1120

NMR δ (CDCl₃): 1.33(3H, d, J=6.15Hz), 1.40(3H, d,
J=6.6Hz), 4.20(2H, br, s), 5.23(2H,
s), 5.84(2H, s), 7.50(2H, d,
J=8.6Hz), 7.65(2H, d, J=8.6Hz),
8.15(2H, d, J=8.6Hz), 8.21(2H, d,
J=8.6Hz)

- 182 -

UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 283

IR $\nu_{\text{max}}^{\text{KBr}}$ (cm⁻¹): 1750, 1640, 1610, 1455, 1400, 1250




HE PNB PNB



HE H H


0126587



D-cis

Example No.	R ₁	R ₂	R ₃	Y	Spectral Data
73	HE	PNZ	PNB	-N(CH ₃) ₂	IR ν _{max} ^{CHCl₃} (cm ⁻¹): 3430, 1775, 1710, 1655, 1525, 1350, 1012 NMR δ (CDCl ₃): 1.34(3H, d, J=6.4Hz), 1.38(3H, d, J=6.8Hz), 2.92, 2.94, 2.98 and 3.08(6H, each s), 5.21(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.6Hz), 7.65(2H, d, J=8.6Hz), 8.21(2H, d, J=8.6Hz)
	HE	H	H	-N(CH ₃) ₂	UV λ _{max} ^{H₂O} nm: 297 IR ν _{max} ^{KBr} (cm ⁻¹): 1755, 1630(sh), 1600, 1380, 1240

0126587



Example
No.

R₁

R₂

R₃

Y

Spectral Data

$[\alpha]_D^{33} +32^\circ$ (c=0.22, THF)

HE PNZ PNB -NH₂

IR $\nu_{\max}^{\text{Nujol}}$ (cm⁻¹): 1780, 1680, 1608, 1517, 1381, 1350

NMR δ (CDCl₃): 1.18(3H, d, J=6Hz), 5.22(2H, s),
5.79(1H, s)

UV $\lambda_{\max}^{\text{H}_2\text{O}}$ nm: 322, 255

HE H H -NH₂

IR ν_{\max}^{KBr} (cm⁻¹): 1762, 1655, 1577, 1376

NMR δ (D₂O): 1.29(3H, d, J=6.5Hz), 1.75-1.89(1H, m), 2.62-2.87(1H, m), 3.00-3.09(1H, m), 3.38-3.48(1H, m), 3.65-3.92(2H, m), 3.90(1H, dd, J=1.4Hz and J=6Hz), 4.17-4.30(1H, m), 5.68(1H, d, J=1.4Hz)

Example
No.

R₁


R₂

R₃

Y

Spectral Data

$[\alpha]_D^{27}$ +48° (c=0.31, CHCl₃)




HE PNZ PNB

CHCl₃ (cm⁻¹): 1790, 1706, 1653, 1612, 1420, 1356,
IR_{max} 1115

NMRδ (CDCl₃): 1.36(3H, d, J=6Hz), 5.22(2H, s),
5.75(1H, d, J=1.5Hz)


KBr (cm⁻¹): 1765, 1636, 1582, 1365
IR_{max}



HE H H

NMRδ (D₂O):


1.29(3H, d, J=6.4Hz), 1.80-2.08(5H, m), 2.88-3.05(1H, m), 3.34-3.61(5H, m), 3.64-3.74(1H, m), 3.93(1H, dd, J=1.4Hz and J=6Hz), 4.04(1H, quin, J=6.6Hz), 4.24(1H, quin, J=6.3Hz), 4.40(1H, t, J=8.2Hz), 5.70(1H, d, J=1.4Hz)



Example No.	R ₁ R ₂ R ₃			Spectral Data	
			Y	IR _{max} (cm ⁻¹):	Nujol 1780, 1700, 1675, 1600, 1505
76	H	PNZ	PNB	-NH ₂	
				NMR _δ (CDCl ₃):	4.40(1H, t, J=7Hz), 5.25(2H, s), 5.37(1H, d, J=13.6Hz), 5.75(1H, dd, J=1.5Hz and J=3.5Hz), 7.47(2H, d, J=9Hz), 7.57(2H, d, J=9Hz), 8.16(4H, d, J=9Hz)












0126587














According to the procedures "described in preceding Examples, the following compounds can also be prepared. In the following Tables, "Ph" means phenyl group.










Compound No.	X	Y
1	-CH ₂ -	-NHC ₂ H ₅
2	-CH ₂ -	-NH-nC ₄ H ₉
3	-CH ₂ -	-NH-iC ₄ H ₉
4	-CH ₂ -	-N(nC ₃ H ₇) ₂
5	-CH ₂ -	-N(iC ₃ H ₇) ₂
6	-CH ₂ -	-N(nC ₄ H ₉) ₂
7	-CH ₂ -	-N(iC ₄ H ₉) ₂
8	-CH ₂ -	-N $\begin{cases} \text{CH}_3 \\ \text{C}_2\text{H}_5 \end{cases}$
9	-CH ₂ -	-N $\begin{cases} \text{C}_2\text{H}_5 \\ \text{nC}_4\text{H}_9 \end{cases}$
10	-CH ₂ -	-N $\begin{cases} \text{H} \\ \text{CH}_2\text{CH}_2\text{Ph} \end{cases}$

Compound No.	X	Y
11	-CH ₂ -	$\begin{array}{c} \text{---N---Ph} \\ \\ \text{CH}_3 \end{array}$
12	-CH ₂ -	$\begin{array}{c} \text{---NCH}_2\text{---Ph} \\ \\ \text{C}_2\text{H}_5 \end{array}$
13	-CH ₂ -	-N(CH ₂ -Ph) ₂
14	-CH ₂ -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\ \\ \text{H} \end{array}$
15	-CH ₂ -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\ \\ \text{CH}_3 \end{array}$
16	-CH ₂ -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\ \\ \text{C}_2\text{H}_5 \end{array}$
17	-CH ₂ -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\ \\ \text{C}_2\text{H}_5 \end{array}$
18	-CH ₂ -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\ \\ \text{H} \end{array}$
19	-CH ₂ -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\ \\ \text{H} \end{array}$
20	-CH ₂ -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\ \\ \text{CH}_3 \end{array}$
21	-CH ₂ -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\ \\ \text{C}_2\text{H}_5 \end{array}$
22	-CH ₂ -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\ \\ \text{C}_2\text{H}_5 \end{array}$
23	-CH ₂ -	$\begin{array}{c} \text{---N---OH} \\ \\ \text{CH}_3 \end{array}$





Compound No.	X	Y
24	-CH ₂ -	
25	-CH ₂ -	
26	-CH ₂ -	
27	-CH ₂ -	
28	-CH ₂ -	
29	-CH ₂ -	
30	-CH ₂ -	
31	-CH ₂ -	
32	-CH ₂ -	
33	-CH ₂ -	
34	-CH ₂ -	


Compound No.	X	Y
35	$-\text{CH}_2-$	
36	$-\text{CH}_2-$	
37	$-\text{CH}_2-$	
38	$-\text{CH}_2-$	
39	$-\text{CH}_2-$	
40	$-\text{CH}_2-$	
41	$-\text{CH}_2-$	
42	$-\text{CH}_2-$	
43	$-\text{CH}_2-$	
44		
45		





0126587

Compound No.	X	Y
46	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{CH}- \end{array}$	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\ \\ \text{H} \end{array}$
47	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{CH}- \end{array}$	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\ \\ \text{CH}_3 \end{array}$
48	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{CH}- \end{array}$	$\begin{array}{c} \text{CONH}_2 \\ \\ \text{---} \end{array}$ 
49	-S-	$\begin{array}{c} \text{---} \\ \\ \text{H} \end{array}$ 
50	-S-	$\begin{array}{c} \text{---} \\ \\ \text{CH}_3 \end{array}$ 
51	-S-	$\begin{array}{c} \text{---} \\ \\ \text{CH}_3 \end{array}$ 
52	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONH}_2 \\ \\ \text{H} \end{array}$
53	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONH} \\ \\ \text{H} \end{array}$ 
54	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\ \\ \text{CH}_3 \end{array}$
55	-S-	
56	-S-	






0126587


Compound No.	X	Y
57	-S-	
58	-S-	
59	-S-	
60	-S-	
61	-S-	-OCH ₃











Compound No.	X	Y
62		
63		


0126587

Compound No.	X	Y
64	-CH ₂ -	
65	-CH ₂ -	
66	-S-	
67	-S-	
68	-S-	
69	-S-	-N(CH ₃) ₂









Compound No.	X	Y
70		

Compound No.	X	Y
71	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{CH}- \end{array}$	
72	$-\text{CH}_2-$	
73	$-\text{CH}_2-$	
74	$-\text{S}-$	
75	$-\text{S}-$	
76	$-\text{S}-$	
77	$-\text{S}-$	$-\text{N}(\text{CH}_3)_2$



Compound No.	X	Y
78		
79		
80		
81		
82		
83		
84		


Compound No.	X	Y
85	-CH ₂ -	
86	-CH ₂ -	
87	-S-	
88	-S-	
89	-S-	
90	-S-	-N(CH ₃) ₂



Compounds No.	Y
91	$-\text{NH}_2$
92	$-\text{N}(\text{CH}_3)\text{CH}_2\text{OH}$
93	$-\text{NHCH}_2\text{CONH}_2$
94	$-\text{N}(\text{CH}_3)\text{CH}_2\text{CONH}_2$
95	$-\text{N}$ (cyclopent-1-en-1-yl)
96	$-\text{N}$ (cyclobut-1-en-1-yl)
97	$-\text{N}$ (4-hydroxycyclopent-1-en-1-yl)
98	$-\text{N}$ (morpholin-2-yl)
99	$-\text{N}$ (N-methylpiperidin-2-yl)
100	$-\text{OCH}_3$

CLAIMS:

1. A β -lactam compound represented by the formula:




- wherein R_1 represents a hydrogen atom, a 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group; R_2 represents a hydrogen atom or a protecting group for an amino group; R_3 represents a hydrogen atom or a protecting group for a carboxyl group; X represents a substituted or unsubstituted methylene group of the formula (1):



- wherein R_4 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or X represents a sulfur atom; and Y represents a group of the formula (2):



wherein R_5 and R_6 , which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety thereof, a substituted alkyl group having 1 to 5 carbon atoms or a pyridyl group, or R_5 and R_6 are taken together to represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C_1-C_3) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof, a substituted or unsubstituted guanidyl group of the formula (3):



wherein R_7 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, a protected or unprotected hydroxyl group, an alkoxy group having 1 to 3 carbon atoms, an unsubstituted or (C_1-C_3) alkyl-substituted hydrazino group or a group of the formula (4):



wherein R_8 represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and a pharmaceutically acceptable salt thereof.

- 5 2. A compound as claimed in Claim 1, wherein R_1 represents a hydrogen atom or a 1-hydroxyethyl group, R_2 and R_3 each represents a hydrogen atom, and Y is a group represented by the formula (2-a):




- 10 wherein R_{5-a} and R_{6-a} each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-(C_1 - C_3)alkylamino group, a carbamoyl group, a mono- or di-(C_1 - C_3)alkyl-substituted aminocarbonyl group or a carboxyl group, or a pyridyl group; or R_{5-a} and R_{6-a} jointly represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C_1 - C_3)alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, an unsubstituted or substituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof wherein the substituent is an alkyl group having
- 15
- 20

1 to 3 carbon atoms, a carbamoyl group, a carboxyl group,
 a mono- or di-(C₁-C₃)alkyl-substituted aminocarbonyl
 group or a hydroxyl group; an unsubstituted or (C₁-C₃)alkyl-
 substituted guanidyl group, a hydroxyl group, an alkoxy group having
 5 1 to 3 carbon atoms, an unsubstituted or substituted
 hydrazino group wherein the substituent is an alkyl
 group having 1 to 3 carbon atoms; or a group represented
 by the formula (4-a):



10 wherein R_{8-a} represents a hydrogen atom or an alkyl group
 having 1 to 3 carbon atoms.

3. A compound as claimed in Claim 1, wherein R₁
 represents a 1-hydroxyethyl group, R₂ and R₃ each
 represents a hydrogen atom, and Y is a group represented
 15 by the formula (2-b):




wherein R_{5-b} and R_{6-b} each represents a hydrogen atom,
 an alkyl group having 1 to 5 carbon atoms, an alkenyl
 group having 3 to 4 carbon atoms, an aralkyl group
 20 having 1 to 3 carbon atoms in the alkyl moiety thereof,
 a substituted alkyl group having 1 to 5 carbon atoms

wherein the substituent is a hydroxyl group, a di-
 (C₁-C₃)alkylamino group, a carbamoyl group, a mono-
 or di-(C₁-C₃)alkyl-substituted aminocarbamoyl group or
 a carboxyl group, or a pyridyl group, or R_{5-b} and R_{6-b}
 5 jointly represent an alkylene chain or an alkylene chain
 via an oxygen atom, a sulfur atom or a (C₁-C₃)alkyl-
 substituted nitrogen atom to form, together with the
 adjacent nitrogen atom, an unsubstituted or substituted
 3- to 7-membered cyclic amino group which may contain
 10 double bond(s) in the ring thereof wherein the substituent
 is an alkyl group having 1 to 3 carbon atoms, a carbamoyl
 group or a hydroxyl group; an unsubstituted or substituted
 guanidyl group wherein the substituent is an alkyl group
 having 1 to 3 carbon atoms; a
 15 hydroxyl group, an alkoxy group having 1 to 3 carbon
 atoms, an unsubstituted or substituted hydrazino group
 wherein the substituent is an alkyl group having 1 to 3
 carbon atoms; or a group represented by the formula (4-a):



20 wherein R_{8-a} represents a hydrogen atom or an alkyl
 group having 1 to 3 carbon atoms.

4. A compound as claimed in Claim 1, wherein R_1 represents a 1-hydroxyethyl group, R_2 and R_3 each represents a hydrogen atom, and Y is a group represented by the formula (2-c):




wherein $R_{5-\text{C}}$ and $R_{6-\text{C}}$ have one of the following meanings:


- (1) $R_{5-\text{C}}$ represents an alkyl group having 1 to 5 carbon atoms which may be substituted with a carbamoyl group, a mono- or di- (C_1-C_3) alkylamino-carbonyl group or a hydroxyl group, or a pyridyl group, and $R_{6-\text{C}}$ represents a hydrogen atom or has the same meaning as defined for $R_{5-\text{C}}$;
- (2) $R_{5-\text{C}}$ and $R_{6-\text{C}}$ jointly represent an alkylene chain to form, together with the adjacent nitrogen atom, an unsubstituted or substituted 4- to 6-membered saturated cyclic amino group or an unsubstituted or substituted 5- to 6-membered cyclic amino group having double bond(s) in the ring thereof wherein the substituent on the cyclic amino ring is a carbamoyl group or a hydroxyl group; and
- (3) $R_{5-\text{C}}$ and $R_{6-\text{C}}$ jointly represent an alkylene chain via an oxygen atom or a (C_1-C_3) alkyl-substituted nitrogen atom to form, together with

the adjacent nitrogen atom, a 6-membered cyclic amino group.

5. A compound as claimed in Claim 3, wherein Y is a group represented by the formula:





wherein R_{5-d} represents a hydrogen atom or a methyl group, and R_{6-d} represents a group of the formula:




wherein R_a , R_b and R_c each represents a hydrogen atom or a methyl group.

6. A compound as claimed in Claim 3, wherein Y is represented by the formula:



or



7. A compound as claimed in any one of Claims 1 to 6, wherein X represents $\begin{array}{c} \text{R}_4 \\ | \\ -\text{CH}- \end{array}$ wherein R_4 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms.

8. A compound as claimed in Claim 7, wherein X represents $\begin{array}{c} \text{CH}_3 \\ | \\ -\text{CH}- \end{array}$.
9. A compound as claimed in Claim 7, wherein R₄ is a hydrogen atom.
- 5 10. A compound as claimed in any one of Claims 1 to 6, wherein X is a sulfur atom.
11. A (5R)-compound of a compound as claimed in any one of Claims 1 to 10.
12. (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio-
10 6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
13. (5R)-3-[2-((1-Pyrrolidino)carbonyl)pyrrolidin-4-ylthio-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-
15 7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
14. (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically
20 acceptable salt thereof.
15. (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutical-
ly acceptable salt thereof.
- 25 16. (5R)-3-[2-((1-Pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically

acceptable salt thereof.

17. (5R)-3-[2-((1-Pyrroli-3-nyl)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

18. (5R)-3-[2-((1-Azetidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutical-ly acceptable salt thereof.

19. (5R)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

20. (5R)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-3-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

21. (5R)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

22. (5R)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutical-ly acceptable salt thereof.

23. (5R)-3-[2-(Methoxycarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 5 24. (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 10 25. (5R)-3-[2-(4-Pyridylaminocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 15 26. (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 20 27. (5R)-3-[2-((1-pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
28. (5R)-3-[2-((1-Pyrroli-3-nyl)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 25 29. (5R)-3-[2-((1-Azatidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic

pharmaceutically acceptable salt thereof.

30. (5R)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid,
5 or a non-toxic pharmaceutically acceptable salt thereof.

31. (5R)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or
a non-toxic pharmaceutically acceptable salt thereof.

10 32. (5R)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

33. (5R)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo-
15 [3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

34. (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-
20 carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

35. (5R)-3-[2-(Methoxycarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically
25 acceptable salt thereof.

36. A (5R,6S,8R)-compound of a compound as claimed in any one of Claims 3 to 35.

37. A (5R,6S,8R,2'S,4'S)-compound of a compound as claimed in any one of Claims 3 to 35.

38. A (4R,5R,6S,8R,2'S,4'S)-compound of a compound as claimed in any one of Claims 3 to 8 and 26 to 35.


5

39. A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of at least one of the compounds as claimed in any preceding claim and at least one pharmaceutically acceptable inert carrier or diluent.


10

40. Use of a compound according to Claim 1 as an antimicrobial agent.

41. A process for preparing a compound as claimed in Claim 1, which comprises reacting a compound of the formula (II):



5 wherein R_1 and X are as defined in Claim 1, R_9 represents a protecting group for a carboxyl group, Z represents a reactive ester of an alcohol, or a substituted or unsubstituted lower-alkyl sulfinyl group, with a mercaptan derivative of the formula:



wherein R_2 is as defined in Claim 1, and Y' is a group represented by the formula (2):




15 wherein R_5 and R_6 are as defined above, an unsubstituted or alkyl-substituted guanidyl group having 1 to 3 carbon atoms in the alkyl moiety, a hydroxyl group protected with a carboxyl protecting group, an alkoxy group having 1 to 3 carbon

atoms, an unsubstituted or substituted hydrazino group wherein the substituent is an alkyl group having 1 to 3 carbon atoms, or a group represented by the formula (4'):



wherein R_8' represents a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, in the presence of a base in an inert solvent to produce a β -lactam compound represented by the formula (IV):



wherein R_1 , R_2 , R_9 , X and Y' are as defined above, and, if desired, subjecting the resulting compound to an appropriate combination of removal of the protecting group for the carboxyl group, the protecting group for the hydroxyl group and/or the protecting group for the amino group, sequentially or simultaneously, to produce the compound of the formula (IV) wherein R_1 is a 1-hydroxyethyl group, R_2 is a hydrogen atom and/or R_3 is a hydrogen atom, or the compound of the formula (IV) wherein the protecting group on the group Y' is removed.



European Patent
Office

EUROPEAN SEARCH REPORT

0126587

Application number

EP 84 30 3128

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
Y	CHEMICAL ABSTRACTS, vol. 98, no. 17, 25th April 1983, page 557, no. 143190w, Columbus, Ohio, US; & JP - A - 57 176 988 (SANKYO CO., LTD.) 30-10-1982 * Abstract *	1,10, 39-41	C 07 D 487/04 C 07 D 499/00 A 61 K 31/40 A 61 K 31/43 // C 07 D 207/16 C 07 D 207/24 C 07 D 401/12 C 07 D 205/08 C 07 F 7/18 C 07 F 9/65 (C 07 D 487/04 C 07 D 209/00 C 07 D 205/00)
Y	EP-A-O 002 210 (MERCK) * Claims *	1,10, 39-41	
Y	EP-A-O 072 710 (SANKYO) * Claims *	1,7,39-41	
Y	EP-A-O 017 992 (MERCK) * Claims and especially claims 8,22 on page 237 above and claim 28 on page 270 above *	1,7,39-41	<div>TECHNICAL FIELDS SEARCHED (Int. Cl. 3)</div> C 07 D 487/00 C 07 D 499/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 09-07-1984	Examiner CHOULY J.
<div>CATEGORY OF CITED DOCUMENTS</div> <div> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </div> <div> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </div>			